General Information of Disease (ID: DIS8WA0W)

Disease Name Carcinoma of liver and intrahepatic biliary tract
Synonyms
hepatocellular carcinoma plus intrahepatic cholangiocarcinoma; cancer of liver; cancer of liver and intrahepatic biliary tract; liver cancer; liver and intrahepatic bile duct cancer; cancer of the liver; liver/hepatobiliary cancer; cancer of the liver and intrahepatic biliary tract; carcinoma of liver; liver carcinoma; hepatic cancer; primary liver carcinoma; liver and intrahepatic biliary tract cancer; liver and intrahepatic bile duct carcinoma; carcinoma of liver and IBT; liver and intrahepatic biliary tract carcinoma
Definition
A carcinoma that arises from the hepatocytes or intrahepatic bile ducts. The main subtypes are hepatocellular carcinoma (hepatoma) and cholangiocarcinoma.|Editor note: In uberon intrahepatic bile ducts are part of the liver, so we equate this with carcinoma of liver; we use hepatocellular for the liver proper
Disease Hierarchy
DISFC6MM: Digestive system carcinoma
DISH9F1N: Carcinoma
DISDE4BI: Liver cancer
DIS8WA0W: Carcinoma of liver and intrahepatic biliary tract
Disease Identifiers
MONDO ID
MONDO_0018531
UMLS CUI
C0279000
MedGen ID
78921
Orphanet ID
424936

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 209 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ABCB4 TTJUXV6 Limited Biomarker [1]
ADAM17 TT6AZXG Limited Biomarker [2]
BCAT1 TTES57P Limited Biomarker [3]
BMI1 TTIPNSR Limited Biomarker [4]
CASP4 TT6KIOT Limited Biomarker [5]
CD160 TTOFEAS Limited Altered Expression [6]
CEACAM1 TTA9CK4 Limited Biomarker [7]
CFD TT8D13I Limited Altered Expression [8]
DKK2 TTST5KX Limited Genetic Variation [9]
DTL TT8396I Limited Biomarker [10]
EHMT2 TTS6RZT Limited Posttranslational Modification [11]
EPCAM TTZ8WH4 Limited Altered Expression [12]
EPHB6 TTZEMUY Limited Biomarker [13]
GDF2 TTAP4T1 Limited Biomarker [14]
GJC1 TTEP7OC Limited Altered Expression [15]
GMPS TTCFP0V Limited Biomarker [16]
GPC3 TTJTSX4 Limited Biomarker [17]
GSTA3 TT29VDX Limited Biomarker [18]
HOXA13 TTN26OM Limited Altered Expression [19]
HOXA7 TTMRE4Q Limited Altered Expression [20]
ID1 TTBXVDE Limited Biomarker [21]
IDUA TT0IUKX Limited Biomarker [22]
KDM4A TTZHPB8 Limited Biomarker [23]
KLRK1 TTLRN4A Limited Biomarker [24]
KMO TTIY56R Limited Biomarker [25]
MAPKAPK2 TTMUG9D Limited Biomarker [26]
MPL TTIHYA4 Limited Biomarker [27]
NDUFA13 TTRU1NG Limited Altered Expression [28]
NEDD4 TT1QU6G Limited Biomarker [29]
NEK2 TT3VZ24 Limited Biomarker [30]
NR1H3 TTECBXN Limited Altered Expression [31]
NUAK2 TTHVOTQ Limited Biomarker [32]
PARG TT39J16 Limited Altered Expression [33]
PIK3CB TT9H4P3 Limited Biomarker [34]
PKD2L1 TTAHD89 Limited Biomarker [35]
PKM TT4LOT8 Limited Biomarker [36]
PTP4A3 TT7YM8D Limited Biomarker [37]
RAB22A TTAJ746 Limited Altered Expression [38]
RTN4R TTVRZUO Limited Biomarker [39]
SIRT5 TTH0IOD Limited Altered Expression [40]
SLC10A1 TTWZRY5 Limited Genetic Variation [41]
SLC13A5 TTFIMH7 Limited Biomarker [42]
SLC3A2 TT5CZSM Limited Biomarker [43]
SPHK1 TTOHFIY Limited Biomarker [44]
SPHK2 TTCN0M9 Limited Biomarker [45]
SULF2 TTLQTHB Limited Biomarker [46]
TBL1X TTAL6S1 Limited Altered Expression [47]
TGFA TTTLQFR Limited Biomarker [48]
TLN1 TTQSMFG Limited Altered Expression [49]
TNFSF10 TTA5MS9 Limited Biomarker [50]
TOP1 TTGTQHC Limited Biomarker [51]
TPX2 TT0PHL4 Limited Biomarker [52]
TRPV2 TTBECWA Limited Biomarker [53]
USP30 TTQ9EDI Limited Biomarker [54]
VDAC1 TTAMKGB Limited Biomarker [55]
YAP1 TT8UN2D Limited Altered Expression [56]
CD44 TTWFBT7 Disputed Genetic Variation [57]
CHUK TT1F8OQ Disputed Biomarker [58]
NCR1 TTQNRJM Disputed Altered Expression [59]
OAT TTTSCQ2 Disputed Genetic Variation [60]
PBK TTMY6BZ Disputed Biomarker [61]
SLC7A11 TTBZMIO Disputed Biomarker [62]
ZWINT TTWY768 Disputed Altered Expression [63]
ANO1 TTOJI4S moderate Genetic Variation [64]
APOBEC3G TTP96KH moderate Genetic Variation [65]
CCNA2 TTAMQ62 moderate Biomarker [66]
CPS1 TT42M75 moderate Altered Expression [67]
ENSA TTQD0YT moderate Biomarker [68]
FER TTRA9G0 moderate Altered Expression [69]
FGF19 TTGCH11 moderate Biomarker [70]
HNRNPA2B1 TT8UPW6 moderate Biomarker [71]
LYVE1 TTG8DNU moderate Altered Expression [72]
MAD1L1 TTNE9U7 moderate Biomarker [73]
MAGEA1 TT63M7Q moderate Altered Expression [74]
MAN2A1 TT34DCN moderate Altered Expression [69]
MSI2 TTTXQF6 moderate Biomarker [75]
NCK1 TTMA3VF moderate Biomarker [76]
PEMT TT735V2 moderate Biomarker [77]
PHB TT6U071 moderate Altered Expression [78]
PINX1 TT4FJ3A moderate Genetic Variation [79]
SRD5A2 TTT02K8 moderate Genetic Variation [80]
TAGLN2 TTP6BIJ moderate Biomarker [81]
TNFRSF25 TTDV6BQ moderate Biomarker [82]
TRIM24 TT9Q7AE moderate Biomarker [83]
TSG101 TTHU7JA moderate Biomarker [84]
TXNRD1 TTR7UJ3 moderate Altered Expression [85]
XRCC5 TTCB9KW moderate Genetic Variation [86]
AKR1B1 TTFBNVI Strong Biomarker [87]
AKR1C3 TT5ZWB6 Strong Altered Expression [88]
ALCAM TT2AFT6 Strong Biomarker [89]
ALDH2 TTFLN4T Strong Altered Expression [90]
AQP9 TTQEI32 Strong Altered Expression [91]
ASPH TT2KHP7 Strong Altered Expression [92]
ATAD2 TT9A0HI Strong Genetic Variation [93]
ATP7B TTOPO51 Strong Biomarker [94]
BMPR2 TTGKF90 Strong Biomarker [95]
CAMKK2 TTV298Y Strong Biomarker [96]
CARM1 TTIZQFJ Strong Biomarker [97]
CD96 TT83C4X Strong Biomarker [98]
CDK2 TT7HF4W Strong Biomarker [99]
CEBPA TT5LWG1 Strong Altered Expression [100]
CXCL11 TTWG0RE Strong Altered Expression [101]
CXCL9 TTWE5PB Strong Biomarker [102]
DCN TTB3XAN Strong Biomarker [103]
DEPDC1 TT8S9CM Strong Biomarker [104]
DKK1 TTE3RAC Strong Biomarker [105]
DNAJB1 TTPXAWS Strong Biomarker [106]
DYRK2 TT84OS6 Strong Altered Expression [107]
E2F1 TTASI04 Strong Altered Expression [108]
E2F2 TT5FYX0 Strong Altered Expression [109]
EPHB2 TTKPV6O Strong Altered Expression [110]
ESRRG TT9ZRHB Strong Altered Expression [111]
FGR TTPOGS1 Strong Biomarker [112]
FHL1 TTI7ENL Strong Altered Expression [113]
FLT4 TTDCBX5 Strong Biomarker [35]
GADD45B TTMDW9L Strong Altered Expression [114]
GCK TTDLNGZ Strong Altered Expression [115]
GGT1 TTZVT7O Strong Altered Expression [116]
GP1BA TTVB0Q9 Strong Biomarker [117]
GRK2 TTAZ3MN Strong Altered Expression [118]
GRN TT0LWE3 Strong Altered Expression [119]
HDAC11 TT8K17W Strong Biomarker [120]
HDAC3 TT4YWTO Strong Biomarker [121]
HGFAC TTD96RW Strong Biomarker [122]
HK2 TTK02H8 Strong Biomarker [123]
HMBS TTT0HW3 Strong Altered Expression [124]
HMGA1 TTBA219 Strong Biomarker [125]
HMGCS2 TTS0EZJ Strong Biomarker [126]
HNRNPA1 TTPJ9XK Strong Altered Expression [127]
HPD TT8DSFC Strong Biomarker [128]
HSD17B4 TTL1WGS Strong Biomarker [129]
HSP90B1 TTFPKXQ Strong Altered Expression [130]
HSPA9 TTMTPG3 Strong Altered Expression [131]
HSPB3 TTLH8WG Strong Biomarker [132]
HSPG2 TT5UM29 Strong Genetic Variation [133]
IFNL3 TTRF4Q2 Strong Genetic Variation [134]
IRS2 TTF95B8 Strong Biomarker [135]
JUN TTS7IR5 Strong Biomarker [136]
KAT2B TTVK7SB Strong Biomarker [34]
KDM1A TTNR0UQ Strong Biomarker [137]
KISS1 TTU2O6T Strong Biomarker [138]
KITLG TTDJ51N Strong Biomarker [139]
KLRC1 TTC4IMS Strong Altered Expression [140]
LAPTM4B TTEJQT0 Strong Biomarker [141]
LATS2 TTML7FG Strong Biomarker [142]
LGR5 TTTSGRH Strong Biomarker [143]
MAGEC2 TTKGUEB Strong Altered Expression [144]
MANF TT56RYE Strong Biomarker [145]
MAP3K10 TT9FN4J Strong Biomarker [146]
MAP3K2 TTIX0ZU Strong Altered Expression [147]
MARCKS TTHRM39 Strong Biomarker [148]
MAT2A TTSMPXQ Strong Biomarker [149]
MSLN TT4RXME Strong Biomarker [150]
MTDH TTH6SA5 Strong Biomarker [151]
NR0B2 TT25A9Q Strong Biomarker [152]
NR1H4 TTS4UGC Strong Biomarker [153]
NR1I3 TTRANFM Strong Biomarker [154]
NUAK1 TT65FL0 Strong Biomarker [155]
PCSK7 TTD30LY Strong Biomarker [156]
PCYT1B TTUAIKM Strong Biomarker [157]
PDCD2 TTYOVWN Strong Biomarker [158]
PLK2 TT976FS Strong Biomarker [159]
PLK4 TTGPNZQ Strong Genetic Variation [160]
PPOX TTNFMS9 Strong Altered Expression [124]
PSMD10 TT2H4LN Strong Biomarker [161]
PTGER3 TTPNGDE Strong Biomarker [162]
RHO TTH0KSX Strong Altered Expression [163]
RIPK1 TTVJHX8 Strong Biomarker [164]
ROS1 TTSZ6Y3 Strong Altered Expression [165]
SATB1 TTLFRIC Strong Biomarker [166]
SCD TT6RIOV Strong Biomarker [167]
SEPTIN6 TTAGE7U Strong Biomarker [168]
SERPINB3 TT6QLPX Strong Biomarker [169]
SERPINC1 TT4QPUL Strong Biomarker [170]
SIRT6 TTUXYWF Strong Biomarker [171]
SLC22A1 TTM5Q4V Strong Biomarker [172]
SLC5A2 TTF8JAT Strong Biomarker [173]
SLC5A5 TTW7HI9 Strong Biomarker [174]
SLC7A5 TTPH2JB Strong Biomarker [175]
SLCO1B1 TTFGXEB Strong Altered Expression [176]
SLCO2B1 TTDL3UZ Strong Altered Expression [176]
SNCG TT5TQNZ Strong Altered Expression [177]
SQSTM1 TTOT2RY Strong Altered Expression [178]
TLR1 TTW14D0 Strong Altered Expression [179]
TNFRSF10A TT5WLRX Strong Biomarker [180]
TNFRSF10B TTW20TU Strong Altered Expression [181]
TRIP10 TTKHTGE Strong Posttranslational Modification [182]
TTK TTP7EGM Strong Biomarker [22]
VSIR TT51SK8 Strong Biomarker [183]
WWP2 TT6TU05 Strong Biomarker [184]
XPO1 TTCJUR4 Strong Biomarker [185]
YOD1 TTFSH0K Strong Biomarker [186]
YY1AP1 TTYED1Q Strong Biomarker [187]
ZNF224 TT1CDXL Strong Altered Expression [104]
ADORA2B TTNE7KG Definitive Biomarker [188]
ANPEP TTPHMWB Definitive Altered Expression [189]
ANXA10 TT0NL6U Definitive Altered Expression [190]
CLIC1 TT8KZG6 Definitive Biomarker [191]
FOLR2 TTT54CI Definitive Altered Expression [192]
HDAC2 TTSHTOI Definitive Biomarker [193]
KRT6A TT2FX8W Definitive Genetic Variation [194]
LILRB2 TTHC6XU Definitive Altered Expression [195]
MAP4K3 TTI0AHJ Definitive Altered Expression [115]
PRKCI TTWJTHX Definitive Biomarker [196]
PROM1 TTXMZ81 Definitive Biomarker [189]
SCAP TTL6U2P Definitive Biomarker [197]
SORD TTLSRBZ Definitive Genetic Variation [194]
TM6SF2 TTE1OHM Definitive Genetic Variation [198]
TMBIM6 TT7QSMG Definitive Biomarker [199]
------------------------------------------------------------------------------------
⏷ Show the Full List of 209 DTT(s)
This Disease Is Related to 4 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC25A11 DT0YAUQ Limited Biomarker [200]
SLCO5A1 DTYVQ5M moderate Biomarker [201]
ABCB5 DTKVEXO Strong Altered Expression [202]
SLC25A21 DT2UQYR Definitive Altered Expression [149]
------------------------------------------------------------------------------------
This Disease Is Related to 19 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
MAT1A DEQ6NC9 Limited Altered Expression [203]
MMEL1 DEYCUQ2 Limited Biomarker [204]
NDUFS7 DEIW03B Limited Biomarker [205]
PCK1 DEPLH5Z Limited Altered Expression [206]
UGP2 DE4U39Y Limited Biomarker [207]
AKR7A2 DE4G629 moderate Biomarker [208]
CPA4 DEXKD7J moderate Altered Expression [209]
SULT1A3 DEP7E8X moderate Altered Expression [210]
UBASH3B DE10BJ5 moderate Biomarker [211]
AKR1B10 DEP6GT1 Strong Biomarker [212]
AKR1C2 DEOY5ZM Strong Altered Expression [88]
DIO3 DET89OV Strong Biomarker [213]
GPT DER5HFI Strong Biomarker [214]
P4HA2 DE5EGK0 Strong Altered Expression [215]
UGT2B7 DEB3CV1 Strong Genetic Variation [216]
AKR1C1 DE7P2FB Definitive Altered Expression [88]
AKR1C4 DEAJN47 Definitive Biomarker [88]
MAT2B DEKF1OH Definitive Biomarker [217]
NAT10 DEZV4AP Definitive Biomarker [218]
------------------------------------------------------------------------------------
⏷ Show the Full List of 19 DME(s)
This Disease Is Related to 431 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ACADL OTP7Y0UF Limited Altered Expression [219]
ACOX1 OTM0A0DY Limited Altered Expression [40]
ACRBP OT0MK3L1 Limited Biomarker [220]
ACSL1 OTB06ESI Limited Biomarker [221]
ACSM3 OT0AE1IV Limited Altered Expression [222]
ACTR3 OT05LJSH Limited Altered Expression [223]
AFAP1L2 OTJBI0VN Limited Altered Expression [224]
AGFG1 OTI8ZKC4 Limited Biomarker [225]
AHNAK OT6KH1WG Limited Posttranslational Modification [226]
AKAP12 OTCVRDDX Limited Biomarker [227]
AKAP17A OT2CEJW4 Limited Biomarker [228]
ALDH7A1 OTV57BZD Limited Altered Expression [229]
AQP5 OT77GBY8 Limited Biomarker [230]
ARSF OTC0L12N Limited Biomarker [231]
BTRC OT2EZDGR Limited Biomarker [232]
CALML3 OTM8DNQU Limited Biomarker [233]
CAND1 OTGB6NU0 Limited Biomarker [234]
CAPN6 OT8K5PR5 Limited Altered Expression [235]
CDCA3 OTUI8QK3 Limited Biomarker [220]
CEBPD OTNBIPMY Limited Biomarker [236]
CERS4 OTV5ENAX Limited Biomarker [237]
CHAF1A OTXSSY4H Limited Biomarker [238]
CHCHD2 OTL5PA3Y Limited Biomarker [239]
CISD2 OTVS7S2H Limited Altered Expression [240]
CLDN3 OT71MN9S Limited Biomarker [241]
CLEC7A OTRTBH27 Limited Altered Expression [242]
CLIC4 OT6KTPKD Limited Biomarker [243]
CUL4A OTTBV70J Limited Biomarker [244]
DACT2 OTNLCC0K Limited Biomarker [245]
DCAF1 OT3ZDVOE Limited Biomarker [225]
DDX3X OTDO4TRX Limited Altered Expression [246]
DEFB1 OT5SV0E4 Limited Biomarker [247]
DEPDC7 OT62C942 Limited Altered Expression [248]
DGKQ OT8OEPYT Limited Biomarker [249]
DKK4 OTWCCVF6 Limited Biomarker [250]
DLC1 OTP8LMCR Limited Genetic Variation [251]
DLEC1 OTMKKBUW Limited Genetic Variation [251]
DPYS OTLTUIVL Limited Biomarker [252]
DYNLL1 OTR69LHT Limited Genetic Variation [251]
E2F7 OTWW358N Limited Biomarker [253]
ECHS1 OTS0593S Limited Biomarker [254]
EIF2B5 OTV3R4RB Limited Altered Expression [255]
FBXL2 OT5EZ7PD Limited Biomarker [256]
FGA OTMIHY80 Limited Biomarker [257]
FHL5 OT6C00Z1 Limited Biomarker [258]
FNDC3B OTBILGDR Limited Biomarker [259]
FSTL5 OT18C29S Limited Biomarker [260]
GALNT14 OT9BSDDQ Limited Genetic Variation [261]
GATAD1 OT0UZ3EP Limited Altered Expression [37]
GNPAT OTF6LWPO Limited Biomarker [54]
GPR107 OTX5VURU Limited Altered Expression [262]
GRIP1 OT958HK1 Limited Biomarker [263]
GTF2H1 OTCRXC6B Limited Altered Expression [178]
HGS OTCYYCAC Limited Biomarker [264]
HHLA2 OTYBTVQS Limited Biomarker [265]
HLF OTTRK9XN Limited Biomarker [266]
HMBOX1 OTPKTBVI Limited Biomarker [267]
HMGB3 OTCJ2EZY Limited Biomarker [268]
HNRNPC OT47AK4C Limited Altered Expression [127]
HNRNPDL OTB3BFCV Limited Altered Expression [127]
HPR OTXSC9UB Limited Biomarker [269]
IER3 OTZJI5FZ Limited Biomarker [270]
IER5 OTJPTXMD Limited Posttranslational Modification [271]
JCAD OT7G1WJW Limited Biomarker [272]
KLF17 OT5NWVP7 Limited Biomarker [273]
KLHDC2 OTBHH882 Limited Biomarker [274]
LAT OTZC1XZ1 Limited Biomarker [175]
MAFG OTBQFUZH Limited Biomarker [275]
MAPK6 OTDDNF3Q Limited Altered Expression [276]
MAVS OTTQ0J64 Limited Biomarker [277]
MBD3 OTRL76H5 Limited Biomarker [136]
MED15 OT0D0JVD Limited Altered Expression [278]
MPEG1 OT7DAO0F Limited Biomarker [22]
NANOG OTUEY1FM Limited Biomarker [220]
NASP OTNE4THC Limited Altered Expression [279]
NCOA1 OTLIUJQD Limited Biomarker [280]
NCR3LG1 OT15YWU7 Limited Biomarker [265]
NCS1 OT6JHAWM Limited Altered Expression [281]
NECTIN2 OTIE0W6O Limited Biomarker [282]
NKD1 OTY3MO97 Limited Altered Expression [283]
NOLC1 OTKDZU0D Limited Biomarker [284]
NR2E3 OTO3GBHQ Limited Biomarker [263]
NUMB OTMB586Q Limited Posttranslational Modification [285]
NUP62 OTMN63DH Limited Altered Expression [178]
ORM1 OTZKSBRE Limited Altered Expression [286]
OSCP1 OTZ4IFGJ Limited Biomarker [287]
PCK2 OTJ8LX4N Limited Altered Expression [206]
PGK1 OT6V1ICH Limited Biomarker [288]
PIWIL1 OT7CRGZ3 Limited Biomarker [289]
PLEC OTU4XDEG Limited Biomarker [290]
POLE OTFM3MMU Limited Genetic Variation [291]
POU2F1 OTK7ELJ0 Limited Altered Expression [235]
PRC1 OTHD0XS0 Limited Biomarker [292]
PREX2 OTYT1J6J Limited Altered Expression [293]
PRRX1 OTTZK5G8 Limited Altered Expression [294]
PSMD14 OTJWHMZ5 Limited Biomarker [295]
PSMD4 OTH1VZTM Limited Biomarker [231]
PTPRO OTFLKWOY Limited Biomarker [296]
RABGEF1 OTWC3Z3R Limited Biomarker [297]
RAD54B OTMWB2P2 Limited Altered Expression [298]
RAMP3 OTX6XLLM Limited Biomarker [299]
RASA2 OTL06RG2 Limited Biomarker [300]
RBM38 OTPO8EXU Limited Altered Expression [301]
RBX1 OTYA1UIO Limited Altered Expression [302]
RECQL4 OT59LSW7 Limited Altered Expression [303]
RFC1 OT3L5PK3 Limited Biomarker [304]
RPA1 OT76POLP Limited Biomarker [305]
RPAIN OTBMXAYK Limited Biomarker [225]
RPS27 OTFXKY7P Limited Biomarker [22]
RSPO2 OT3HHXU0 Limited Biomarker [306]
SAMHD1 OTBCIBC7 Limited Genetic Variation [307]
SARS1 OTFKXQ1O Limited Biomarker [308]
SARS2 OTU4T99W Limited Biomarker [308]
SASH1 OTQA8BD4 Limited Altered Expression [309]
SETD3 OTO5RAU2 Limited Altered Expression [310]
SF3B4 OTGB9OR9 Limited Biomarker [311]
SIRT4 OT5S0J23 Limited Biomarker [312]
SND1 OTT734JN Limited Altered Expression [313]
SNX10 OT05B7BT Limited Altered Expression [314]
SOCS2 OTBPNKJQ Limited Biomarker [315]
SPOP OTP0107S Limited Biomarker [316]
SPRTN OT01D5CE Limited Biomarker [317]
SRCIN1 OTQZNQQ5 Limited Biomarker [318]
SULF1 OTJCNCO0 Limited Biomarker [150]
SUZ12 OT655XF8 Limited Altered Expression [319]
TCIM OTARUXQF Limited Biomarker [320]
TERF2IP OT3M5P3G Limited Biomarker [297]
TEX10 OTNTU9CB Limited Altered Expression [321]
TFDP1 OT6RZ7VT Limited Biomarker [322]
TLN2 OT10QQBC Limited Altered Expression [49]
TM4SF5 OTPAV531 Limited Altered Expression [323]
TP53INP1 OT2363Z9 Limited Biomarker [324]
TRAP1 OTNG0L8J Limited Altered Expression [325]
TRIB2 OTHSX3MX Limited Biomarker [326]
CD5L OTPY4WQR Disputed Altered Expression [327]
CMTM7 OTI7Q2JW Disputed Biomarker [328]
DVL1 OTD67RF1 Disputed Biomarker [329]
ELOVL6 OTB26UJJ Disputed Altered Expression [330]
FHL2 OT0OAYWT Disputed Altered Expression [331]
FZD6 OTBCPII8 Disputed Biomarker [332]
GDF11 OTOSNMND Disputed Biomarker [333]
GOLPH3 OTDLGYM3 Disputed Biomarker [334]
GTSF1 OTV7PQJF Disputed Altered Expression [335]
KIF18A OTSMBJ24 Disputed Altered Expression [336]
MORC2 OT52A8BJ Disputed Altered Expression [337]
RHEB OTFLTSEC Disputed Altered Expression [338]
RIT1 OTVNOGOH Disputed Biomarker [339]
SFMBT2 OTZQT61Q Disputed Altered Expression [340]
THY1 OTVONVTB Disputed Altered Expression [12]
ACOT7 OT7C68YV moderate Biomarker [258]
ACTBL2 OTD6B81U moderate Biomarker [258]
ADAR OTQNOHR8 moderate Altered Expression [341]
ANAPC11 OTK2SJXR moderate Biomarker [342]
ARNT OTMSIEZY moderate Biomarker [343]
ASL OTI2NGQR moderate Biomarker [344]
CD151 OTF3UZS7 moderate Biomarker [345]
CLIP1 OTTGAEJE moderate Biomarker [346]
CLIP2 OTSCIQIY moderate Biomarker [346]
CPEB4 OTW1SCZW moderate Altered Expression [347]
CRYL1 OT0SJSJM moderate Altered Expression [348]
CSMD1 OTIVDSC4 moderate Biomarker [349]
DIRAS3 OT3XHLQA moderate Altered Expression [350]
DRAM1 OTIJTXEN moderate Altered Expression [351]
EIF2S1 OTM0GDTP moderate Biomarker [352]
EIF2S2 OTXF0B09 moderate Biomarker [352]
EIF2S3 OTARRES9 moderate Biomarker [352]
ELK1 OTH9MXD6 moderate Biomarker [353]
FADD OTV7GFHH moderate Genetic Variation [64]
FOXK1 OTLZGS7J moderate Biomarker [354]
FUBP1 OT77SC9N moderate Biomarker [355]
HCFC1 OT0UCK62 moderate Genetic Variation [356]
ING3 OTDIJXFP moderate Altered Expression [357]
KCNH4 OTHJ8WTU moderate Biomarker [353]
KCNH8 OT3I5FLB moderate Biomarker [353]
LDB2 OT6Y8IEK moderate Biomarker [358]
LMNB1 OT100T3P moderate Biomarker [359]
LTO1 OTQ17ZDT moderate Genetic Variation [64]
MAGED4B OTO37U7W moderate Altered Expression [74]
MAML1 OTQA4DDN moderate Altered Expression [360]
MAP1S OT5WUD4C moderate Biomarker [361]
MASTL OTQ7YKK5 moderate Altered Expression [68]
MLXIPL OTR9MLLW moderate Biomarker [362]
MNT OTPC4ANL moderate Biomarker [76]
MPP1 OTA2ENZQ moderate Altered Expression [363]
MRGPRF OT74OZ2Z moderate Biomarker [364]
NLK OT2LETFS moderate Biomarker [365]
OSGIN1 OT9KIVZW moderate Biomarker [366]
PCDH20 OTFSNRXK moderate Altered Expression [367]
PEA15 OTKCKTSX moderate Biomarker [368]
PIK3R3 OTXGJ8N1 moderate Altered Expression [363]
POLG2 OTDBMZJB moderate Altered Expression [363]
POTEM OT7L2HGH moderate Biomarker [258]
PPFIA1 OTYYFA9C moderate Genetic Variation [64]
PRICKLE1 OT9HHEM9 moderate Biomarker [369]
PSMD12 OTWICA51 moderate Altered Expression [363]
PTMA OT2W4T1M moderate Altered Expression [370]
RAE1 OT54OKC3 moderate Biomarker [371]
RBFOX2 OTXY1WVH moderate Biomarker [364]
RGN OTD04KB1 moderate Altered Expression [372]
RNASE7 OTIXO0Z4 moderate Biomarker [371]
RPIA OT805SMH moderate Altered Expression [373]
SCARA5 OTOVA96E moderate Posttranslational Modification [374]
SFPQ OTLCIAPJ moderate Biomarker [375]
SH3BP4 OTVIRKW7 moderate Posttranslational Modification [376]
SHMT2 OT5NCAZN moderate Biomarker [377]
TIGAR OTR7NMRJ moderate Posttranslational Modification [378]
TNFAIP8L2 OTII0RM0 moderate Altered Expression [379]
TRIM3 OT704FQ0 moderate Altered Expression [380]
TSPY1 OTPY57X4 moderate Altered Expression [381]
TSPY3 OTQK3AKI moderate Altered Expression [381]
ACYP2 OTRB4S6X Strong Genetic Variation [382]
ANXA3 OTDD8OI7 Strong Biomarker [383]
ANXA7 OTLMD0TK Strong Biomarker [384]
APOBEC3A OTYO6F5P Strong Altered Expression [223]
APOBEC3B OTHLNI51 Strong Genetic Variation [385]
ARHGAP1 OT0H2ZBZ Strong Biomarker [386]
ARHGAP9 OTJNHX96 Strong Altered Expression [387]
ARID2 OTIRJXWM Strong Genetic Variation [388]
ARR3 OTRZ00CH Strong Biomarker [154]
ATF7 OTM8T3OD Strong Altered Expression [389]
AXIN2 OTRMGQNU Strong Biomarker [390]
B3GAT3 OTDSN5XF Strong Biomarker [391]
BIN1 OTK8O0X8 Strong Biomarker [375]
BIRC6 OTCQJAB0 Strong Biomarker [392]
BRI3BP OTWCFPRM Strong Biomarker [393]
BTBD7 OTNUV6MQ Strong Genetic Variation [394]
CADM1 OTRWG9QS Strong Posttranslational Modification [395]
CALD1 OTNJKJ6Q Strong Biomarker [396]
CAMK4 OT47RDGV Strong Biomarker [96]
CBX5 OT8VYY84 Strong Genetic Variation [397]
CCL28 OTY6XNQ7 Strong Biomarker [398]
CCN6 OTRFHQ2Z Strong Biomarker [399]
CDCA5 OTZLCQ5U Strong Biomarker [400]
CELF1 OT6JQ5RS Strong Genetic Variation [401]
CHD1L OT7CZK7C Strong Biomarker [402]
CHD4 OTBDEHDP Strong Biomarker [403]
CIAPIN1 OTWS90F9 Strong Altered Expression [404]
CIRBP OTXWTPBL Strong Biomarker [405]
CKS1B OTNUPLUJ Strong Biomarker [406]
CPQ OTTNZNLD Strong Altered Expression [407]
CPSF7 OT4WE5J7 Strong Biomarker [408]
CPT1A OTI862QH Strong Altered Expression [409]
CTBS OT135K92 Strong Biomarker [157]
CTTN OTJRG4ES Strong Genetic Variation [64]
CXADR OT9ZP02A Strong Biomarker [154]
CYGB OTX153DQ Strong Biomarker [410]
DCTN6 OTI8PIN9 Strong Altered Expression [411]
DERL2 OTI3TUUZ Strong Altered Expression [412]
DEUP1 OTXLM86J Strong Posttranslational Modification [413]
DHX9 OT5AAOQI Strong Biomarker [375]
ETNPPL OTSXO9P6 Strong Altered Expression [414]
EXO1 OTI87RS5 Strong Altered Expression [415]
FAH OTGZA1YR Strong Genetic Variation [416]
FAM83H OTN0SF11 Strong Biomarker [417]
FBP1 OTQBANEP Strong Altered Expression [418]
FHL3 OTMPRLZ5 Strong Biomarker [419]
FOXA1 OTEBY0TD Strong Altered Expression [420]
FOXL2 OTFRQUYL Strong Altered Expression [421]
FSD1 OT8P6PT3 Strong Biomarker [422]
FSD1L OTBQ48RF Strong Biomarker [422]
FUNDC1 OTA6IVKQ Strong Biomarker [423]
FXYD5 OT81DIOD Strong Biomarker [424]
GEMIN4 OTX7402E Strong Biomarker [425]
GGPS1 OTVEHG28 Strong Altered Expression [426]
GNMT OT0O2OQO Strong Altered Expression [427]
GOLM1 OTOZSV6O Strong Biomarker [428]
GSC OT4DH7PR Strong Biomarker [429]
H3C1 OTGBGOZW Strong Altered Expression [421]
HACE1 OTEZULKD Strong Biomarker [430]
HFE OTDD93KB Strong Biomarker [431]
HLA-DRB4 OTNXIHQU Strong Genetic Variation [432]
HSPB2 OTS01646 Strong Biomarker [132]
IFI27 OTI2XGIT Strong Altered Expression [411]
IFT88 OTDR3VBD Strong Biomarker [433]
ILF2 OTWWVM9X Strong Biomarker [434]
IQGAP1 OTZRWTGA Strong Biomarker [435]
IQGAP2 OTX2UA7P Strong Biomarker [435]
ITGA7 OTTBTAYW Strong Altered Expression [436]
JUNB OTG2JXV5 Strong Altered Expression [437]
KAT5 OTL7257A Strong Biomarker [438]
KCNK17 OTG2NEZM Strong Altered Expression [439]
KLF11 OTKVQDJD Strong Biomarker [440]
KRT10 OTSVRD3Q Strong Biomarker [441]
KRT23 OTQW6UAG Strong Biomarker [442]
LAMTOR5 OTER0U8L Strong Altered Expression [443]
LDLRAD4 OTQUX50Z Strong Biomarker [444]
LETMD1 OTZTZ4RD Strong Biomarker [393]
LGALS3BP OT9AGQKH Strong Biomarker [445]
LOXL4 OT6XY2JL Strong Altered Expression [446]
LRATD1 OT65IL83 Strong Biomarker [447]
MAK16 OTD546E5 Strong Altered Expression [448]
MAP2K3 OTI2OREX Strong Biomarker [449]
MARCHF1 OTI2EYO6 Strong Biomarker [450]
MARVELD1 OT5CPOJE Strong Altered Expression [451]
MEF2D OT7CEIG0 Strong Biomarker [452]
METTL3 OTSXP1M3 Strong Altered Expression [453]
MFN2 OTPYN8A3 Strong Biomarker [454]
MICA OTPEIEAR Strong Altered Expression [455]
MIEF1 OTFSP3FS Strong Biomarker [456]
MOB2 OTMBE0NS Strong Biomarker [187]
MPST OTCDPH5D Strong Biomarker [146]
MRPS5 OTZZR208 Strong Biomarker [457]
MSTO1 OT37XCNP Strong Biomarker [146]
MT1H OT0MVBM6 Strong Altered Expression [458]
MXD1 OTS5CTHX Strong Biomarker [76]
NCOA2 OTMQFPBB Strong Biomarker [112]
NDRG2 OT5L6KD7 Strong Biomarker [459]
NONO OTN36Q6U Strong Biomarker [375]
NPC2 OTE9UEJC Strong Biomarker [460]
NUPR1 OT4FU8C0 Strong Biomarker [461]
NUSAP1 OT85HIJ5 Strong Altered Expression [462]
OGT OT1Z1ZXE Strong Altered Expression [463]
OIP5 OTI5C2DE Strong Altered Expression [95]
PADI2 OTT40K94 Strong Altered Expression [464]
PAEP OTQA0NV4 Strong Biomarker [396]
PBX3 OT8WMVM4 Strong Altered Expression [147]
PCLAF OTMVIOUU Strong Genetic Variation [465]
PDE6D OTIFVXWD Strong Altered Expression [110]
PDZD7 OTX3VAOB Strong Altered Expression [466]
PES1 OTMZK7XE Strong Biomarker [467]
PFKM OT1QY9JM Strong Biomarker [468]
PLAAT4 OTI66SAJ Strong Biomarker [11]
PNO1 OT010GIS Strong Altered Expression [448]
POLR2E OTH5IL2A Strong Genetic Variation [469]
PPIL3 OT0GPU73 Strong Biomarker [470]
PPP2R3A OTSK5GFC Strong Altered Expression [471]
PRKAA1 OT7TNF0L Strong Biomarker [454]
PRKAA2 OTU1KZPV Strong Biomarker [454]
PRKAB1 OT1OG4QZ Strong Biomarker [454]
PRPF31 OTSJ0Z1Y Strong Altered Expression [472]
PSMD9 OT6Y5CC3 Strong Altered Expression [411]
PSMG2 OTEMF20S Strong Genetic Variation [473]
RASAL1 OTAHUNN7 Strong Biomarker [474]
RBMS3 OTFSC9MR Strong Altered Expression [448]
RDX OTNSYUN6 Strong Altered Expression [475]
RECQL OTPCH3JH Strong Biomarker [476]
RGS5 OTUY0Q2I Strong Altered Expression [477]
RIN2 OTCY73U9 Strong Biomarker [478]
RIOX2 OT2YFPI2 Strong Biomarker [479]
RNF17 OTKOEPRW Strong Biomarker [480]
RNF187 OTXTN1HP Strong Altered Expression [481]
RNGTT OT59E0KX Strong Biomarker [425]
RPE OT0XT3JU Strong Biomarker [482]
RPRD1B OTB41D5K Strong Biomarker [483]
RTN3 OTGZ51QF Strong Biomarker [346]
RUVBL1 OTWV19L7 Strong Biomarker [484]
SAFB OTGRV2LW Strong Biomarker [346]
SALL4 OTC08PR5 Strong Altered Expression [485]
SAV1 OTSAEV92 Strong Altered Expression [135]
SCTR OTC80IMR Strong Altered Expression [486]
SEPTIN2 OT3G33TM Strong Biomarker [168]
SERPINA11 OTXM6IJM Strong Altered Expression [487]
SHARPIN OTU1J2KH Strong Altered Expression [488]
SIRT7 OT5M4OT4 Strong Biomarker [489]
SMURF1 OT5UIZR8 Strong Biomarker [232]
SOCS5 OTN1ABYR Strong Biomarker [490]
SPAG9 OT45AHMB Strong Altered Expression [449]
SPIN1 OT69VAOX Strong Biomarker [491]
SPRY2 OTH0CRCZ Strong Posttranslational Modification [492]
SPZ1 OTQH8HJ5 Strong Biomarker [438]
SRA1 OTYOGMTG Strong Altered Expression [280]
SRRM2 OTSIMMC9 Strong Altered Expression [448]
SRSF1 OTF61HOV Strong Biomarker [231]
STARD13 OTB4U1HY Strong Biomarker [386]
TARBP1 OT14Z6RJ Strong Altered Expression [493]
TBX3 OTM64N7K Strong Biomarker [494]
THEM4 OTSIZU8Y Strong Biomarker [495]
TIAM2 OTPYIPT6 Strong Biomarker [496]
TICAM2 OTK7GIJ5 Strong Altered Expression [411]
TIGD1 OTEQ4UT0 Strong Biomarker [497]
TIPRL OTS2FZ8O Strong Biomarker [498]
TJP1 OTBDCUPK Strong Altered Expression [499]
TM4SF4 OTRI8EHN Strong Biomarker [500]
TMED7 OTONO8E6 Strong Altered Expression [411]
TMEM176A OTOZDWXX Strong Biomarker [501]
TMEM176B OTEGF2BV Strong Genetic Variation [501]
TMEM74 OT3IZBM0 Strong Biomarker [502]
TMEM82 OTURDYCZ Strong Altered Expression [487]
TMEM9 OTXC0JXR Strong Biomarker [503]
TMOD3 OTQPNSTH Strong Altered Expression [504]
TOP1MT OT2H77ID Strong Biomarker [505]
TRADD OTBOSJHO Strong Altered Expression [506]
TRAF3 OT5TQBGV Strong Biomarker [507]
TRIM13 OTQIUACB Strong Biomarker [154]
TRO OTRZQMU8 Strong Biomarker [508]
TROAP OTC8CE0R Strong Altered Expression [509]
TRRAP OT68OI2Y Strong Biomarker [510]
ALX4 OTNS9A29 Definitive Biomarker [511]
AP1M1 OT1IR6CD Definitive Biomarker [512]
APOBEC2 OT4CCS0Q Definitive Altered Expression [513]
ARF6 OTVV7KJO Definitive Altered Expression [514]
ATP8B1 OTALGS63 Definitive Genetic Variation [515]
ATRNL1 OTY5JUX2 Definitive Biomarker [218]
BCAP31 OTKSACR4 Definitive Biomarker [396]
BMPR1A OTQOA4ZH Definitive Altered Expression [516]
CBX3 OTOP9RLD Definitive Biomarker [517]
CDKN3 OTBE3H07 Definitive Altered Expression [518]
CENPM OTYK9KOX Definitive Biomarker [519]
CITED2 OT812TV7 Definitive Altered Expression [520]
CLDN7 OTNE0XHQ Definitive Biomarker [521]
DIS3L2 OTWABM04 Definitive Biomarker [522]
EPS8 OTZ6ES6V Definitive Biomarker [523]
EPS8L3 OT7XYA2T Definitive Biomarker [523]
GADD45G OT8V1J4M Definitive Biomarker [524]
HNRNPU OTLQN1E2 Definitive Biomarker [522]
IKBKG OTNWJWSD Definitive Altered Expression [525]
IRF2BP2 OTSSRRCA Definitive Biomarker [526]
KPNA2 OTU7FOE6 Definitive Biomarker [108]
LARP4B OT2HI0QE Definitive Biomarker [527]
MRPL38 OTCE2I7M Definitive Genetic Variation [194]
MTMR14 OTUUEY6Q Definitive Biomarker [528]
NR2F2 OTJFS67N Definitive Biomarker [529]
NUP155 OTIIAH4E Definitive Biomarker [530]
OGDHL OT1AZK6R Definitive Altered Expression [531]
OTUD1 OTE6O5XB Definitive Biomarker [532]
PDLIM3 OTVXQC81 Definitive Biomarker [218]
PGM5 OTEAS7OC Definitive Biomarker [533]
PHKB OTKXZZIU Definitive Biomarker [534]
PLXNA3 OTMZIBVG Definitive Genetic Variation [535]
PPP1R11 OTSHYPPW Definitive Biomarker [536]
RALA OT734R7X Definitive Altered Expression [537]
RAN OT2TER5M Definitive Altered Expression [538]
RRBP1 OT4ZTPTM Definitive Biomarker [396]
SIVA1 OTDT0XZK Definitive Altered Expression [539]
SUMO2 OT1Y5IKN Definitive Biomarker [540]
SUMO3 OTTUJQJ1 Definitive Biomarker [540]
SVEP1 OTOBICRD Definitive Genetic Variation [194]
SYTL2 OTUIOWKL Definitive Biomarker [541]
TCF7L1 OTTUTF0O Definitive Biomarker [542]
TFCP2 OTA246TE Definitive Biomarker [543]
TRIM29 OT2DNESG Definitive Biomarker [544]
------------------------------------------------------------------------------------
⏷ Show the Full List of 431 DOT(s)

References

1 ABCB4 missense mutations D243A, K435T, G535D, I490T, R545C, and S978P significantly impair the lipid floppase and likely predispose to secondary pathologies in the human population.Cell Mol Life Sci. 2017 Jul;74(13):2513-2524. doi: 10.1007/s00018-017-2472-6. Epub 2017 Feb 20.
2 Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival.Scand J Gastroenterol. 2018 Oct-Nov;53(10-11):1368-1375. doi: 10.1080/00365521.2018.1517277. Epub 2018 Nov 5.
3 Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma.Cancer Res. 2018 Aug 15;78(16):4731-4744. doi: 10.1158/0008-5472.CAN-17-2459. Epub 2018 Jun 18.
4 Biocompatible co-loading vehicles for delivering both nanoplatin cores and siRNA to treat hepatocellular carcinoma.Int J Pharm. 2019 Dec 15;572:118769. doi: 10.1016/j.ijpharm.2019.118769. Epub 2019 Oct 26.
5 Cytisine induces endoplasmic reticulum stress caused by calcium overload in HepG2 cells.Oncol Rep. 2018 Mar;39(3):1475-1484. doi: 10.3892/or.2018.6200. Epub 2018 Jan 8.
6 Reduced CD160 Expression Contributes to Impaired NK-cell Function and Poor Clinical Outcomes in Patients with HCC.Cancer Res. 2018 Dec 1;78(23):6581-6593. doi: 10.1158/0008-5472.CAN-18-1049. Epub 2018 Sep 19.
7 Levels of HBx, VEGF, and CEACAM1 in HBV-related hepatocellular carcinoma and their correlation with cancer prognosis.Eur Rev Med Pharmacol Sci. 2017 Oct;21(17):3827-3833.
8 In vivo inhibitory activity of andrographolide derivative ADN-9 against liver cancer and its mechanisms involved in inhibition of tumor angiogenesis.Toxicol Appl Pharmacol. 2017 Jul 15;327:1-12. doi: 10.1016/j.taap.2017.04.022. Epub 2017 Apr 22.
9 Increased liver carcinogenesis and enrichment of stem cell properties in livers of Dickkopf 2 (Dkk2) deleted mice.Oncotarget. 2016 May 17;7(20):28903-13. doi: 10.18632/oncotarget.3293.
10 Targeting DTL induces cell cycle arrest and senescence and suppresses cell growth and colony formation through TPX2 inhibition in human hepatocellular carcinoma cells.Onco Targets Ther. 2018 Mar 21;11:1601-1616. doi: 10.2147/OTT.S147453. eCollection 2018.
11 Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3.J Hepatol. 2017 Oct;67(4):758-769. doi: 10.1016/j.jhep.2017.05.015. Epub 2017 May 19.
12 TGF-1 accelerates the hepatitis B virus X-induced malignant transformation of hepatic progenitor cells by upregulating miR-199a-3p.Oncogene. 2020 Feb;39(8):1807-1820. doi: 10.1038/s41388-019-1107-9. Epub 2019 Nov 18.
13 Graphene OxidePEGProtocatechuic Acid Nanocomposite Formulation with Improved Anticancer Properties.Nanomaterials (Basel). 2018 Oct 11;8(10):820. doi: 10.3390/nano8100820.
14 Bone morphogenetic protein-9 is a potent growth inhibitor of hepatocellular carcinoma and reduces the liver cancer stem cells population.Oncotarget. 2016 Nov 8;7(45):73754-73768. doi: 10.18632/oncotarget.12062.
15 High glucose stimulates proliferative capacity of liver cancer cells possibly via O-GlcNAcylation-dependent transcriptional regulation of GJC1.J Cell Physiol. 2018 Jan;234(1):606-618. doi: 10.1002/jcp.26803. Epub 2018 Aug 5.
16 Proteomic Analysis Reveals GMP Synthetase as p53 Repression Target in Liver Cancer.Am J Pathol. 2017 Feb;187(2):228-235. doi: 10.1016/j.ajpath.2016.09.022. Epub 2016 Dec 7.
17 XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti-PD-1 Efficacy.Cancer Immunol Res. 2020 Jan;8(1):81-93. doi: 10.1158/2326-6066.CIR-19-0210. Epub 2019 Oct 30.
18 Participation of liver stem cells in cholangiocarcinogenesis after aflatoxin B(1) exposure of glutathione S-transferase A3 knockout mice.Tumour Biol. 2018 May;40(5):1010428318777344. doi: 10.1177/1010428318777344.
19 High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models.Lab Invest. 2018 Jan;98(1):95-105. doi: 10.1038/labinvest.2017.107. Epub 2017 Oct 16.
20 HOXA7 plays a critical role in metastasis of liver cancer associated with activation of Snail.Mol Cancer. 2016 Sep 6;15(1):57. doi: 10.1186/s12943-016-0540-4.
21 Inhibitor of differentiation 1 transcription factor promotes metabolic reprogramming in hepatocellular carcinoma cells.FASEB J. 2016 Jan;30(1):262-75. doi: 10.1096/fj.15-277749. Epub 2015 Sep 1.
22 TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.Br J Pharmacol. 2017 Jun;174(12):1810-1825. doi: 10.1111/bph.13782. Epub 2017 Apr 22.
23 HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372.Oncotarget. 2017 Jul 25;8(30):49093-49109. doi: 10.18632/oncotarget.17095.
24 The Paradoxical Role of NKG2D in Cancer Immunity.Front Immunol. 2018 Aug 13;9:1808. doi: 10.3389/fimmu.2018.01808. eCollection 2018.
25 Identifying Key Genes of Liver Cancer by Networking of Multiple Data Sets.IEEE/ACM Trans Comput Biol Bioinform. 2018 Oct 5. doi: 10.1109/TCBB.2018.2874238. Online ahead of print.
26 Mitogen-activated protein kinase-activated protein kinase 2 mediates resistance to hydrogen peroxide-induced oxidative stress in human hepatobiliary cancer cells.Free Radic Biol Med. 2015 Dec;89:34-46. doi: 10.1016/j.freeradbiomed.2015.07.011. Epub 2015 Jul 11.
27 Biological Response Modifier in Cancer Immunotherapy.Adv Exp Med Biol. 2016;909:69-138. doi: 10.1007/978-94-017-7555-7_2.
28 Taurolidine promotes cell apoptosis by enhancing GRIM?9 expression in liver cancer.Oncol Rep. 2018 Dec;40(6):3743-3751. doi: 10.3892/or.2018.6711. Epub 2018 Sep 18.
29 NEDD4 promotes cell growth and motility in hepatocellular carcinoma.Cell Cycle. 2018;17(6):728-738. doi: 10.1080/15384101.2018.1440879. Epub 2018 Apr 10.
30 Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression.Int J Cancer. 2017 Apr 1;140(7):1581-1596. doi: 10.1002/ijc.30559. Epub 2017 Jan 19.
31 TO901317 inhibits the development of hepatocellular carcinoma by LXR/Glut1 decreasing glycometabolism.Am J Physiol Gastrointest Liver Physiol. 2019 May 1;316(5):G598-G607. doi: 10.1152/ajpgi.00061.2018. Epub 2019 Feb 28.
32 NUAK2 is a critical YAP target in liver cancer.Nat Commun. 2018 Nov 16;9(1):4834. doi: 10.1038/s41467-018-07394-5.
33 PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models.BMC Cancer. 2014 Aug 20;14:603. doi: 10.1186/1471-2407-14-603.
34 K-Ras-PI3K regulates H3K56ac through PCAF to elevate the occurrence and growth of liver cancer.J Cell Physiol. 2020 Apr;235(4):3905-3915. doi: 10.1002/jcp.29284. Epub 2019 Oct 22.
35 Therapeutic Effect of Sorafenib-Loaded TPGS-b-PCL Nanoparticles on Liver Cancer.J Biomed Nanotechnol. 2018 Feb 1;14(2):396-403. doi: 10.1166/jbn.2018.2529.
36 Long noncoding RNA MEG3 suppresses liver cancer cells growth through inhibiting -catenin by activating PKM2 and inactivating PTEN.Cell Death Dis. 2018 Feb 15;9(3):253. doi: 10.1038/s41419-018-0305-7.
37 Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3.Hepatology. 2018 Jun;67(6):2302-2319. doi: 10.1002/hep.29750. Epub 2018 Mar 23.
38 Rab22a enhances CD147 recycling and is required for lung cancer cell migration and invasion.Exp Cell Res. 2017 Aug 1;357(1):9-16. doi: 10.1016/j.yexcr.2017.04.020. Epub 2017 Apr 19.
39 A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis.Mol Carcinog. 2017 May;56(5):1395-1404. doi: 10.1002/mc.22600. Epub 2017 Jan 4.
40 SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer.EMBO Rep. 2018 May;19(5):e45124. doi: 10.15252/embr.201745124. Epub 2018 Feb 28.
41 The Loss-of-Function S267F Variant in HBV Receptor NTCP Reduces Human Risk for HBV Infection and Disease Progression.J Infect Dis. 2018 Sep 22;218(9):1404-1410. doi: 10.1093/infdis/jiy355.
42 Flipping a citrate switch on liver cancer cells.J Biol Chem. 2017 Aug 18;292(33):13902-13903. doi: 10.1074/jbc.H117.783860.
43 Basigin-mediated redistribution of CD98 promotes cell spreading and tumorigenicity in hepatocellular carcinoma.J Exp Clin Cancer Res. 2015 Oct 6;34:110. doi: 10.1186/s13046-015-0226-6.
44 Deletion of sphingosine kinase 1 inhibits liver tumorigenesis in diethylnitrosamine-treated mice.Oncotarget. 2018 Feb 26;9(21):15635-15649. doi: 10.18632/oncotarget.24583. eCollection 2018 Mar 20.
45 MicroRNA-338-3p Suppresses Proliferation of Human Liver Cancer Cells by Targeting SphK2.Oncol Res. 2018 Sep 14;26(8):1183-1189. doi: 10.3727/096504018X15151495109394. Epub 2018 Jan 10.
46 Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer.Oncogene. 2018 Aug;37(32):4443-4454. doi: 10.1038/s41388-018-0291-3. Epub 2018 May 3.
47 Identification of copy number variation-driven genes for liver cancer via bioinformatics analysis.Oncol Rep. 2014 Nov;32(5):1845-52. doi: 10.3892/or.2014.3425. Epub 2014 Aug 20.
48 Generation of liver-specific TGF- and c-Myc-overexpressing fibroblasts for future creation of a liver cancer porcine model.Mol Med Rep. 2014 Jul;10(1):329-35. doi: 10.3892/mmr.2014.2217. Epub 2014 May 7.
49 Talin-1 correlates with reduced invasion and migration in human hepatocellular carcinoma cells.Asian Pac J Cancer Prev. 2014;15(6):2655-61. doi: 10.7314/apjcp.2014.15.6.2655.
50 Suppression of miR-21-3p enhances TRAIL-mediated apoptosis in liver cancer stem cells by suppressing the PI3K/Akt/Bad cascade via regulating PTEN.Cancer Manag Res. 2019 Jan 22;11:955-968. doi: 10.2147/CMAR.S183328. eCollection 2019.
51 DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride.Int J Oncol. 2018 Nov;53(5):1897-1912. doi: 10.3892/ijo.2018.4531. Epub 2018 Aug 21.
52 Effect and mechanism of lentivirus-mediated silencing of TPX2 gene on proliferation and apoptosis of human hepatoma cells.J Cell Biochem. 2019 May;120(5):8352-8358. doi: 10.1002/jcb.28119. Epub 2018 Dec 11.
53 Transient receptor potential vanilloid-type 2 targeting on stemness in liver cancer.Biomed Pharmacother. 2018 Sep;105:697-706. doi: 10.1016/j.biopha.2018.06.029. Epub 2018 Jun 12.
54 Amplification of Glyceronephosphate O-Acyltransferase and Recruitment of USP30 Stabilize DRP1 to Promote Hepatocarcinogenesis.Cancer Res. 2018 Oct 15;78(20):5808-5819. doi: 10.1158/0008-5472.CAN-18-0340. Epub 2018 Aug 24.
55 Targeting Liver Cancer and Associated Pathologies in Mice with a Mitochondrial VDAC1-Based Peptide.Neoplasia. 2018 Jun;20(6):594-609. doi: 10.1016/j.neo.2018.02.012. Epub 2018 May 7.
56 miR-424-5p Regulates Hepatoma Cell Proliferation and Apoptosis.Cancer Biother Radiopharm. 2019 Apr;34(3):196-202. doi: 10.1089/cbr.2018.2625. Epub 2019 Jan 24.
57 A comprehensive study of CD44 rs 187115 variant and cancer risk in a central Chinese population.J Cell Biochem. 2019 Aug;120(8):12949-12957. doi: 10.1002/jcb.28566. Epub 2019 Mar 12.
58 Inhibition of MALAT1 sensitizes liver cancer cells to 5-flurouracil by regulating apoptosis through IKK/NF-B pathway.Biochem Biophys Res Commun. 2018 Jun 18;501(1):33-40. doi: 10.1016/j.bbrc.2018.04.116. Epub 2018 May 7.
59 MiR-544 promotes immune escape through downregulation of NCR1/NKp46 via targeting RUNX3 in liver cancer.Cancer Cell Int. 2018 Apr 3;18:52. doi: 10.1186/s12935-018-0542-y. eCollection 2018.
60 Mechanism of Inactivation of Ornithine Aminotransferase by (1S,3S)-3-Amino-4-(hexafluoropropan-2-ylidenyl)cyclopentane-1-carboxylic Acid.J Am Chem Soc. 2019 Jul 10;141(27):10711-10721. doi: 10.1021/jacs.9b03254. Epub 2019 Jun 28.
61 Glycycoumarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis.Nutrients. 2018 Mar 15;10(3):353. doi: 10.3390/nu10030353.
62 Overexpression of SLC7A11: a novel oncogene and an indicator of unfavorable prognosis for liver carcinoma.Future Oncol. 2018 Apr;14(10):927-936. doi: 10.2217/fon-2017-0540. Epub 2018 Mar 12.
63 Bioinformatic analysis of prognostic value of ZW10 interacting protein in lung cancer.Onco Targets Ther. 2018 Mar 23;11:1683-1695. doi: 10.2147/OTT.S149012. eCollection 2018.
64 Comparative genomics on mammalian Fgf3-Fgf4 locus.Int J Oncol. 2005 Jul;27(1):281-5.
65 Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus.Curr Opin Infect Dis. 2008 Jun;21(3):298-303. doi: 10.1097/QCO.0b013e3282fe1bb2.
66 Structure and expression of the cyclin A gene in human primary liver cancer. Correlation with flow cytometric parameters.J Hepatol. 1995 Jul;23(1):47-52. doi: 10.1016/0168-8278(95)80310-6.
67 DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma.Am J Pathol. 2011 Feb;178(2):652-61. doi: 10.1016/j.ajpath.2010.10.023.
68 ENSA expression correlates with attenuated tumor propagation in liver cancer.Biochem Biophys Res Commun. 2013 Dec 6;442(1-2):56-61. doi: 10.1016/j.bbrc.2013.10.165. Epub 2013 Nov 8.
69 MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.Gastroenterology. 2017 Oct;153(4):1120-1132.e15. doi: 10.1053/j.gastro.2016.12.036. Epub 2017 Feb 27.
70 Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.Cancer Cell. 2011 Mar 8;19(3):347-58. doi: 10.1016/j.ccr.2011.01.040.
71 Up-regulation and subcellular localization of hnRNP A2/B1 in the development of hepatocellular carcinoma.BMC Cancer. 2010 Jul 6;10:356. doi: 10.1186/1471-2407-10-356.
72 LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis.Cancer Res. 2001 Nov 15;61(22):8079-84.
73 Role of a novel splice variant of mitotic arrest deficient 1 (MAD1), MAD1beta, in mitotic checkpoint control in liver cancer.Cancer Res. 2008 Nov 15;68(22):9194-201. doi: 10.1158/0008-5472.CAN-08-2600.
74 Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.Chin Med J (Engl). 2002 Jul;115(7):1002-5.
75 Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.Cancer Lett. 2017 Jan 1;384:50-59. doi: 10.1016/j.canlet.2016.10.007. Epub 2016 Oct 6.
76 Identification of Max binding protein as a novel binding protein of Nck1 and characterization of its role in inhibiting human liver cancer SK-HEP-1 cells.Chin Med J (Engl). 2012 Sep;125(18):3336-9.
77 Identification of three novel cDNAs for human phosphatidylethanolamine N-methyltransferase and localization of the human gene on chromosome 17p11.2.Biochim Biophys Acta. 1999 Jan 4;1436(3):405-12. doi: 10.1016/s0005-2760(98)00147-7.
78 Can Prohibitin 1 be a Safeguard against liver disease?.Ann Hepatol. 2019 Nov-Dec;18(6):790-795. doi: 10.1016/j.aohep.2019.07.012. Epub 2019 Sep 11.
79 Mutation analysis of novel human liver-related putative tumor suppressor gene in hepatocellular carcinoma.World J Gastroenterol. 2003 Jan;9(1):89-93. doi: 10.3748/wjg.v9.i1.89.
80 Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients.J Hepatol. 2003 Oct;39(4):564-70. doi: 10.1016/s0168-8278(03)00355-6.
81 A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility.Oncogene. 2011 Nov 3;30(44):4464-75. doi: 10.1038/onc.2011.161. Epub 2011 May 16.
82 Lupeol, a dietary triterpene, inhibited growth, and induced apoptosis through down-regulation of DR3 in SMMC7721 cells.Cancer Invest. 2009 Feb;27(2):163-70. doi: 10.1080/07357900802210745.
83 Tripartite motif 24 (Trim24/Tif1) tumor suppressor protein is a novel negative regulator of interferon (IFN)/signal transducers and activators of transcription (STAT) signaling pathway acting through retinoic acid receptor (Rar) inhibition.J Biol Chem. 2011 Sep 23;286(38):33369-79. doi: 10.1074/jbc.M111.225680. Epub 2011 Jul 18.
84 Analysis of aberrant transcription of TSG101 in hepatocellular carcinomas.Eur J Cancer. 1999 Feb;35(2):302-8. doi: 10.1016/s0959-8049(98)00356-6.
85 Statins inhibit expression of thioredoxin reductase 1 in rat and human liver and reduce tumour development.Biochem Biophys Res Commun. 2012 Jan 20;417(3):1046-51. doi: 10.1016/j.bbrc.2011.12.091. Epub 2011 Dec 26.
86 Genetic polymorphisms in DNA repair genes XRCC4 and XRCC5 and aflatoxin B1-related hepatocellular carcinoma.Epidemiology. 2013 Sep;24(5):671-81. doi: 10.1097/EDE.0b013e31829d2744.
87 Aldose reductase interacts with AKT1 to augment hepatic AKT/mTOR signaling and promote hepatocarcinogenesis.Oncotarget. 2017 May 10;8(40):66987-67000. doi: 10.18632/oncotarget.17791. eCollection 2017 Sep 15.
88 AKR1C1-3, notably AKR1C3, are distinct biomarkers for liver cancer diagnosis and prognosis: Database mining in malignancies.Oncol Lett. 2019 Nov;18(5):4515-4522. doi: 10.3892/ol.2019.10802. Epub 2019 Sep 4.
89 CD166 plays a pro-carcinogenic role in liver cancer cells via inhibition of FOXO proteins through AKT.Oncol Rep. 2014 Aug;32(2):677-83. doi: 10.3892/or.2014.3226. Epub 2014 May 30.
90 Silencing transcription factor FOXM1 represses proliferation, migration, and invasion while inducing apoptosis of liver cancer stem cells by regulating the expression of ALDH2.IUBMB Life. 2020 Feb;72(2):285-295. doi: 10.1002/iub.2166. Epub 2019 Oct 3.
91 Aquaporin 9 inhibits hepatocellular carcinoma through up-regulating FOXO1 expression.Oncotarget. 2016 Jul 12;7(28):44161-44170. doi: 10.18632/oncotarget.10143.
92 MiR-200a inhibits cell proliferation and EMT by down-regulating the ASPH expression levels and affecting ERK and PI3K/Akt pathways in human hepatoma cells.Am J Transl Res. 2018 Apr 15;10(4):1117-1130. eCollection 2018.
93 ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection.Cancer Res Treat. 2015 Oct;47(4):853-61. doi: 10.4143/crt.2014.177. Epub 2015 Feb 16.
94 ATP7B Binds Ruthenium(II) p-Cymene Half-Sandwich Complexes: Role of Steric Hindrance and Ru-I Coordination in Rescuing the Sequestration.Inorg Chem. 2019 Nov 18;58(22):15659-15670. doi: 10.1021/acs.inorgchem.9b02780. Epub 2019 Oct 28.
95 Overexpression of Opa interacting protein5 increases the progression of liver cancer via BMPR2/JUN/CHEK1/RAC1 dysregulation.Oncol Rep. 2019 Apr;41(4):2075-2088. doi: 10.3892/or.2019.7006. Epub 2019 Feb 11.
96 The camKK2/camKIV relay is an essential regulator of hepatic cancer.Hepatology. 2015 Aug;62(2):505-20. doi: 10.1002/hep.27832. Epub 2015 May 9.
97 AMPK-ERK/CARM1 Signaling Pathways Affect Autophagy of Hepatic Cells in Samples of Liver Cancer Patients.Front Oncol. 2019 Nov 14;9:1247. doi: 10.3389/fonc.2019.01247. eCollection 2019.
98 Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma.Hepatology. 2019 Jul;70(1):168-183. doi: 10.1002/hep.30347. Epub 2019 Mar 5.
99 miR372 Promotes Progression of Liver Cancer Cells by Upregulating erbB-2 through Enhancement of YB-1.Mol Ther Nucleic Acids. 2018 Jun 1;11:494-507. doi: 10.1016/j.omtn.2018.04.001. Epub 2018 Apr 12.
100 Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.Oncogene. 2018 Jun;37(24):3216-3228. doi: 10.1038/s41388-018-0126-2. Epub 2018 Mar 7.
101 CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells.Eur J Cancer. 2012 Jan;48(1):138-48. doi: 10.1016/j.ejca.2011.06.044. Epub 2011 Jul 19.
102 An alternatively spliced variant of CXCR3 mediates the metastasis of CD133+ liver cancer cells induced by CXCL9.Oncotarget. 2016 Mar 22;7(12):14405-14. doi: 10.18632/oncotarget.7360.
103 Tumor-specific inhibitory action of decorin on different hepatoma cell lines.Cell Signal. 2019 Oct;62:109354. doi: 10.1016/j.cellsig.2019.109354. Epub 2019 Jul 2.
104 DEP domain containing 1 suppresses apoptosis via inhibition of A20 expression, which activates the nuclear factor B signaling pathway in HepG2 cells.Oncol Lett. 2018 Jul;16(1):949-955. doi: 10.3892/ol.2018.8770. Epub 2018 May 22.
105 Recent Progress of Wnt Pathway Inhibitor Dickkopf-1 in Liver Cancer.J Nanosci Nanotechnol. 2018 Aug 1;18(8):5192-5206. doi: 10.1166/jnn.2018.14636.
106 Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma.Sci Rep. 2017 Mar 17;7:44653. doi: 10.1038/srep44653.
107 Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer.Cancer Lett. 2019 Jun 1;451:100-109. doi: 10.1016/j.canlet.2019.02.046. Epub 2019 Mar 6.
108 Karyopherin 2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer.Cell Commun Signal. 2019 Nov 29;17(1):159. doi: 10.1186/s12964-019-0456-x.
109 LncRNA ZEB1-AS1 reduces liver cancer cell proliferation by targeting miR-365a-3p.Exp Ther Med. 2019 May;17(5):3539-3547. doi: 10.3892/etm.2019.7358. Epub 2019 Mar 7.
110 The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression.Cancers (Basel). 2019 Mar 21;11(3):398. doi: 10.3390/cancers11030398.
111 Estrogen-related receptor is upregulated in liver cancer and its inhibition suppresses liver cancer cell proliferation via induction of p21 and p27.Exp Mol Med. 2016 Mar 4;48(3):e213. doi: 10.1038/emm.2015.115.
112 Correction: SRC-2-mediated coactivation of anti-tumorigenic target genes suppresses MYC-induced liver cancer.PLoS Genet. 2018 Apr 11;14(4):e1007344. doi: 10.1371/journal.pgen.1007344. eCollection 2018 Apr.
113 Epigenetic analysis of FHL1 tumor suppressor gene in human liver cancer. Oncol Lett. 2017 Nov;14(5):6109-6116.
114 Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma. Am J Pathol. 2003 Jun;162(6):1961-74.
115 MAP4K3/GLK in autoimmune disease, cancer and aging.J Biomed Sci. 2019 Oct 22;26(1):82. doi: 10.1186/s12929-019-0570-5.
116 Rapidly quantitative analysis of -glutamyltranspeptidase activity in the lysate and blood via a rational design of the molecular probe by matrix-assisted laser desorption ionization mass spectrometry.Talanta. 2019 Dec 1;205:120141. doi: 10.1016/j.talanta.2019.120141. Epub 2019 Jul 9.
117 Platelet GPIb is a mediator and potential interventional target for NASH and subsequent liver cancer.Nat Med. 2019 Apr;25(4):641-655. doi: 10.1038/s41591-019-0379-5. Epub 2019 Apr 1.
118 Development of Inflammatory Immune Response-Related Drugs Based on G Protein-Coupled Receptor Kinase 2.Cell Physiol Biochem. 2018;51(2):729-745. doi: 10.1159/000495329. Epub 2018 Nov 21.
119 Novel biomarkers GEP/ABCB5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma.Hepatobiliary Pancreat Dis Int. 2018 Dec;17(6):524-530. doi: 10.1016/j.hbpd.2018.10.003. Epub 2018 Oct 29.
120 Inhibition of histone deacetylase 11 promotes human liver cancer cell apoptosis.Am J Transl Res. 2019 Feb 15;11(2):983-990. eCollection 2019.
121 HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition.Cancer Res. 2019 Jul 15;79(14):3676-3688. doi: 10.1158/0008-5472.CAN-18-3767. Epub 2019 May 16.
122 HGFAC expression decreased in liver cancer and its low expression correlated with DNA hypermethylation and poor prognosis.J Cell Biochem. 2019 Jun;120(6):9692-9699. doi: 10.1002/jcb.28247. Epub 2019 Jan 11.
123 miR-885-5p Negatively Regulates Warburg Effect by Silencing Hexokinase 2 in Liver Cancer.Mol Ther Nucleic Acids. 2019 Dec 6;18:308-319. doi: 10.1016/j.omtn.2019.09.002. Epub 2019 Sep 12.
124 Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias.J Hepatol. 2015 Mar;62(3):734-8. doi: 10.1016/j.jhep.2014.11.029. Epub 2014 Nov 28.
125 Adenovirus-Mediated Delivery of Decoy Hyper Binding Sites Targeting Oncogenic HMGA1 Reduces Pancreatic and Liver Cancer Cell Viability.Mol Ther Oncolytics. 2018 Jan 31;8:52-61. doi: 10.1016/j.omto.2018.01.002. eCollection 2018 Mar 30.
126 HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma.Cancers (Basel). 2019 Nov 26;11(12):1876. doi: 10.3390/cancers11121876.
127 Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development.RNA. 2014 Apr;20(4):505-15. doi: 10.1261/rna.042259.113. Epub 2014 Feb 26.
128 Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.Lancet. 1992 Oct 3;340(8823):813-7. doi: 10.1016/0140-6736(92)92685-9.
129 17hydroxysteroid dehydrogenase4 induces liver cancer proliferationassociated genes via STAT3 activation.Oncol Rep. 2019 Mar;41(3):2009-2019. doi: 10.3892/or.2019.6981. Epub 2019 Jan 23.
130 Glucose-regulated protein of 94 kDa contributes to the development of an aggressive phenotype in breast cancer cells.Biomed Pharmacother. 2018 Sep;105:115-120. doi: 10.1016/j.biopha.2018.05.106. Epub 2018 May 28.
131 Expression of mortalin detected in human liver cancer by tissue microarrays.Anat Rec (Hoboken). 2011 Aug;294(8):1344-51. doi: 10.1002/ar.21433. Epub 2011 Jun 28.
132 SUMOylation of HSP27 by small ubiquitin-like modifier 2/3 promotes proliferation and invasion of hepatocellular carcinoma cells.Cancer Biol Ther. 2017 Aug 3;18(8):552-559. doi: 10.1080/15384047.2017.1345382. Epub 2017 Jun 30.
133 The impact of combined sewage overflows on the viral contamination of receiving waters.Food Environ Virol. 2012 Mar;4(1):34-40. doi: 10.1007/s12560-011-9076-3. Epub 2012 Jan 14.
134 The influence of interleukin 28B polymorphisms on the risk of hepatocellular carcinoma among patients with HBV or HCV infection: An updated meta-analysis.Medicine (Baltimore). 2019 Sep;98(38):e17275. doi: 10.1097/MD.0000000000017275.
135 Insulin receptor substrate 2: a bridge between Hippo and AKT pathways.BMB Rep. 2018 May;51(5):209-210. doi: 10.5483/bmbrep.2018.51.5.095.
136 MBD3 inhibits formation of liver cancer stem cells.Oncotarget. 2017 Jan 24;8(4):6067-6078. doi: 10.18632/oncotarget.13496.
137 LSD1 Stimulates Cancer-Associated Fibroblasts to Drive Notch3-Dependent Self-Renewal of Liver Cancer Stem-like Cells.Cancer Res. 2018 Feb 15;78(4):938-949. doi: 10.1158/0008-5472.CAN-17-1236. Epub 2017 Dec 19.
138 KISS1/KISS1R in Cancer: Friend or Foe?.Front Endocrinol (Lausanne). 2018 Aug 3;9:437. doi: 10.3389/fendo.2018.00437. eCollection 2018.
139 Ubiquitin E3 ligase SCF(-TRCP) regulates TRIB2 stability in liver cancer cells.Biochem Biophys Res Commun. 2013 Nov 22;441(3):555-9. doi: 10.1016/j.bbrc.2013.10.123. Epub 2013 Nov 5.
140 High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer.Oncoimmunology. 2016 Dec 7;6(1):e1264562. doi: 10.1080/2162402X.2016.1264562. eCollection 2017.
141 AP4 positively regulates LAPTM4B to promote hepatocellular carcinoma growth and metastasis, while reducing chemotherapy sensitivity.Mol Oncol. 2018 Mar;12(3):373-390. doi: 10.1002/1878-0261.12171. Epub 2018 Feb 6.
142 Anti-tumor effect of LATS2 on liver cancer death: Role of DRP1-mediated mitochondrial division and the Wnt/-catenin pathway.Biomed Pharmacother. 2019 Jun;114:108825. doi: 10.1016/j.biopha.2019.108825. Epub 2019 Apr 11.
143 Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5(+) liver cancer initiating cells by suppressing negative regulators of -catenin signaling.Oncogene. 2015 Jun 11;34(24):3188-98. doi: 10.1038/onc.2015.129. Epub 2015 Apr 20.
144 MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition.Onco Targets Ther. 2019 Sep 24;12:7843-7855. doi: 10.2147/OTT.S213164. eCollection 2019.
145 Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-B/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.Hepatology. 2020 Apr;71(4):1262-1278. doi: 10.1002/hep.30917. Epub 2020 Jan 26.
146 Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching.Hepatol Res. 2019 Aug;49(8):919-928. doi: 10.1111/hepr.13348. Epub 2019 May 13.
147 miR-302a inhibits human HepG2 and SMMC-7721 cells proliferation and promotes apoptosis by targeting MAP3K2 and PBX3.Sci Rep. 2019 Feb 14;9(1):2032. doi: 10.1038/s41598-018-38435-0.
148 Withdrawal:The long noncoding RNA lncZic2 drives the self-renewal of liver tumor-initiating cells via the protein kinase C substrates MARCKS and MARCKSL1.J Biol Chem. 2018 May 25;293(21):7982-7992. doi: 10.1074/jbc.RA117.001321. Epub 2018 Mar 27.
149 Polyamine and methionine adenosyltransferase 2A crosstalk in human colon and liver cancer.Exp Cell Res. 2013 Jul 15;319(12):1902-1911. doi: 10.1016/j.yexcr.2013.04.005. Epub 2013 Apr 12.
150 Sulfatase-1 knockdown promotes in vitro and in vivo aggressive behavior of murine hepatocarcinoma Hca-P cells through up-regulation of mesothelin.J Cell Commun Signal. 2018 Sep;12(3):603-613. doi: 10.1007/s12079-017-0411-9. Epub 2017 Dec 23.
151 Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway.Tumour Biol. 2016 May;37(5):5885-95. doi: 10.1007/s13277-015-4456-1. Epub 2015 Nov 21.
152 A Novel Small Molecule Activator of Nuclear Receptor SHP Inhibits HCC Cell Migration via Suppressing Ccl2.Mol Cancer Ther. 2016 Oct;15(10):2294-2301. doi: 10.1158/1535-7163.MCT-16-0153. Epub 2016 Aug 2.
153 FXR-Gankyrin axis is involved in development of pediatric liver cancer.Carcinogenesis. 2017 Jul 1;38(7):738-747. doi: 10.1093/carcin/bgx050.
154 High-Content Analysis of Constitutive Androstane Receptor Nuclear Translocation.Methods Mol Biol. 2019;1966:71-77. doi: 10.1007/978-1-4939-9195-2_6.
155 MiR-204 inhibits hepatocellular cancer drug resistance and metastasis through targeting NUAK1.Biochem Cell Biol. 2019 Oct;97(5):563-570. doi: 10.1139/bcb-2018-0354. Epub 2019 Feb 26.
156 Effective Combined Photodynamic Therapy with Lipid Platinum Chloride Nanoparticles Therapies of Oral Squamous Carcinoma Tumor Inhibition.J Clin Med. 2019 Dec 2;8(12):2112. doi: 10.3390/jcm8122112.
157 TPP-related mitochondrial targeting copper (II) complex induces p53-dependent apoptosis in hepatoma cells through ROS-mediated activation of Drp1.Cell Commun Signal. 2019 Nov 19;17(1):149. doi: 10.1186/s12964-019-0468-6.
158 PDCD2 sensitizes HepG2 cells to sorafenib by suppressing epithelialmesenchymal transition.Mol Med Rep. 2019 Mar;19(3):2173-2179. doi: 10.3892/mmr.2019.9860. Epub 2019 Jan 15.
159 Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma.Hepatology. 2010 Mar;51(3):857-68. doi: 10.1002/hep.23467.
160 A cis-eQTL genetic variant in PLK4 confers high risk of hepatocellular carcinoma.Cancer Med. 2019 Oct;8(14):6476-6484. doi: 10.1002/cam4.2487. Epub 2019 Sep 6.
161 Arctigenin Inhibits Liver Cancer Tumorigenesis by Inhibiting Gankyrin Expression via C/EBP and PPAR.Front Pharmacol. 2018 Mar 27;9:268. doi: 10.3389/fphar.2018.00268. eCollection 2018.
162 Prostaglandin E2 promotes human cholangiocarcinoma cell proliferation, migration and invasion through the upregulation of -catenin expression via EP3-4 receptor.Oncol Rep. 2015 Aug;34(2):715-26. doi: 10.3892/or.2015.4043. Epub 2015 Jun 9.
163 Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.Cancer Res. 2005 Oct 1;65(19):8861-8. doi: 10.1158/0008-5472.CAN-05-1318.
164 RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer.Cancer Cell. 2017 Jan 9;31(1):94-109. doi: 10.1016/j.ccell.2016.11.009. Epub 2016 Dec 22.
165 Genistein-triggered anticancer activity against liver cancer cell line HepG2 involves ROS generation, mitochondrial apoptosis, G2/M cell cycle arrest and inhibition of cell migration.Arch Med Sci. 2019 Jul;15(4):1001-1009. doi: 10.5114/aoms.2018.78742. Epub 2018 Oct 3.
166 Hepatitis B Virus X Protein Induces SATB1 Expression Through Activation of ERK and p38MAPK Pathways to Suppress Anoikis.Dig Dis Sci. 2019 Nov;64(11):3203-3214. doi: 10.1007/s10620-019-05681-9. Epub 2019 May 30.
167 Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids via the ATP-AMPK-mTOR-SREBP1 signaling pathway.FASEB J. 2019 Sep;33(9):10089-10103. doi: 10.1096/fj.201802619RR. Epub 2019 Jun 14.
168 The phosphorylation of SEPT2 on Ser218 by casein kinase 2 is important to hepatoma carcinoma cell proliferation.Mol Cell Biochem. 2009 May;325(1-2):61-7. doi: 10.1007/s11010-008-0020-2. Epub 2009 Jan 23.
169 SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity.Sci Rep. 2015 Dec 4;5:17701. doi: 10.1038/srep17701.
170 Gene expression profiling of human HBV- and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags.Int J Oncol. 2006 Aug;29(2):315-27.
171 Histone deacetylase SIRT6 regulates chemosensitivity in liver cancer cells via modulation of FOXO3 activity.Oncol Rep. 2018 Dec;40(6):3635-3644. doi: 10.3892/or.2018.6770. Epub 2018 Oct 8.
172 Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1.Clin Pharmacol Ther. 2020 Jan;107(1):227-237. doi: 10.1002/cpt.1588. Epub 2019 Sep 3.
173 Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.Int J Cancer. 2018 Apr 15;142(8):1712-1722. doi: 10.1002/ijc.31193. Epub 2017 Dec 12.
174 Potential usefulness of baculovirus-mediated sodium-iodide symporter reporter gene as non-invasively gene therapy monitoring in liver cancer cells: an in vitro evaluation.Technol Cancer Res Treat. 2014 Apr;13(2):139-48. doi: 10.7785/tcrt.2012.500368. Epub 2013 Aug 2.
175 Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.Int J Mol Sci. 2018 Jul 19;19(7):2093. doi: 10.3390/ijms19072093.
176 Expression of OATP family members in hormone-related cancers: potential markers of progression.PLoS One. 2011;6(5):e20372. doi: 10.1371/journal.pone.0020372. Epub 2011 May 19.
177 Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration.Int J Oncol. 2006 May;28(5):1081-8.
178 p62 functions as an oncogene in colorectal cancer through inhibiting apoptosis and promoting cell proliferation by interacting with the vitamin D receptor.Cell Prolif. 2019 May;52(3):e12585. doi: 10.1111/cpr.12585. Epub 2019 Feb 22.
179 Experimental and bioinformatics comparison of gene expression between T cells from TIL of liver cancer and T cells from UniGene.J Gastroenterol. 2002;37(4):275-82. doi: 10.1007/s005350200035.
180 Betulinic acid promotes TRAIL function on liver cancer progression inhibition through p53/Caspase-3 signaling activation.Biomed Pharmacother. 2017 Apr;88:349-358. doi: 10.1016/j.biopha.2017.01.034. Epub 2017 Jan 21.
181 Luteolin sensitizes human liver cancer cells to TRAILinduced apoptosis via autophagy and JNKmediated death receptor 5 upregulation.Int J Oncol. 2019 Feb;54(2):665-672. doi: 10.3892/ijo.2018.4633. Epub 2018 Nov 14.
182 Functional characterization of Trip10 in cancer cell growth and survival. J Biomed Sci. 2011 Feb 7;18:12.
183 Investigation of PD-1H in DEN-induced mouse liver cancer model.Eur Rev Med Pharmacol Sci. 2018 Aug;22(16):5194-5199. doi: 10.26355/eurrev_201808_15716.
184 Inhibition of WWP2 suppresses proliferation, and induces G1 cell cycle arrest and apoptosis in liver cancer cells.Mol Med Rep. 2016 Mar;13(3):2261-6. doi: 10.3892/mmr.2016.4771. Epub 2016 Jan 13.
185 CRISPR-Cas9 Screening of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Cells Identifies XPO1 as a Vulnerable Target of Cancer Cells.mBio. 2019 May 14;10(3):e00866-19. doi: 10.1128/mBio.00866-19.
186 Deubiquitinase YOD1 potentiates YAP/TAZ activities through enhancing ITCH stability.Proc Natl Acad Sci U S A. 2017 May 2;114(18):4691-4696. doi: 10.1073/pnas.1620306114. Epub 2017 Apr 17.
187 Identification and characterization of a novel human hepatocellular carcinoma-associated gene.Br J Cancer. 2001 Oct 19;85(8):1162-7. doi: 10.1054/bjoc.2001.2059.
188 HIF-1 regulates A2B adenosine receptor expression in liver cancer cells.Exp Ther Med. 2019 Dec;18(6):4231-4240. doi: 10.3892/etm.2019.8081. Epub 2019 Oct 7.
189 Aberrant expression of CD13 and stem cell markers in CD133-induced liver cancer in mice.J BUON. 2019 Jul-Aug;24(4):1408-1413.
190 Expression levels and prognostic values of annexins in liver cancer.Oncol Lett. 2019 Dec;18(6):6657-6669. doi: 10.3892/ol.2019.11025. Epub 2019 Oct 30.
191 MicroRNA?24 negatively regulates chloride intracellular channel1 to suppress the migration and invasion of liver cancer cells.Oncol Rep. 2019 Oct;42(4):1380-1390. doi: 10.3892/or.2019.7250. Epub 2019 Jul 25.
192 Folic acid conjugated polymeric drug delivery vehicle for targeted cancer detection in hepatocellular carcinoma.J Biomed Mater Res A. 2019 Nov;107(11):2522-2535. doi: 10.1002/jbm.a.36758. Epub 2019 Aug 2.
193 Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2.Cancer Res. 2014 Sep 1;74(17):4752-61. doi: 10.1158/0008-5472.CAN-13-3531. Epub 2014 Jun 23.
194 A novel knowledge-derived data potentizing method revealed unique liver cancer-associated genetic variants.Hum Genomics. 2019 Jul 4;13(1):30. doi: 10.1186/s40246-019-0213-7.
195 The Expression of ILT4 in Myeloid Dendritic Cells in Patients with Hepatocellular Carcinoma.Immunol Invest. 2019 Oct;48(7):704-718. doi: 10.1080/08820139.2019.1571507. Epub 2019 May 2.
196 Role and mechanism of circ-PRKCI in hepatocellular carcinoma.World J Gastroenterol. 2019 Apr 28;25(16):1964-1974. doi: 10.3748/wjg.v25.i16.1964.
197 RA-XII Suppresses the Development and Growth of Liver Cancer by Inhibition of Lipogenesis via SCAP-dependent SREBP Supression.Molecules. 2019 May 12;24(9):1829. doi: 10.3390/molecules24091829.
198 Association of TM6SF2 rs58542926 T/C gene polymorphism with hepatocellular carcinoma: a meta-analysis.BMC Cancer. 2019 Nov 21;19(1):1128. doi: 10.1186/s12885-019-6173-4.
199 Expression of TMBIM6 in Cancers: The Involvement of Sp1 and PKC.Cancers (Basel). 2019 Jul 11;11(7):974. doi: 10.3390/cancers11070974.
200 The 2-oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading.Redox Biol. 2018 Apr;14:164-177. doi: 10.1016/j.redox.2017.08.022. Epub 2017 Sep 14.
201 The analysis of organic anion transporting polypeptide (OATP) mRNA and protein patterns in primary and metastatic liver cancer.Cancer Biol Ther. 2011 May 1;11(9):801-11. doi: 10.4161/cbt.11.9.15176. Epub 2011 May 1.
202 Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance.Gastroenterology. 2011 Jan;140(1):344-55. doi: 10.1053/j.gastro.2010.07.049. Epub 2010 Aug 2.
203 Role of promoter methylation in increased methionine adenosyltransferase 2A expression in human liver cancer. Am J Physiol Gastrointest Liver Physiol. 2001 Feb;280(2):G184-90.
204 Enhanced antitumor activity of gemcitabine by polysaccharide-induced NK cell activation and immune cytotoxicity reduction in vitro/vivo.Carbohydr Polym. 2017 Oct 1;173:360-371. doi: 10.1016/j.carbpol.2017.06.024. Epub 2017 Jun 10.
205 Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study.Lancet HIV. 2018 Nov;5(11):e647-e655. doi: 10.1016/S2352-3018(18)30179-6. Epub 2018 Sep 21.
206 Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma.Oncogene. 2018 Mar;37(12):1637-1653. doi: 10.1038/s41388-017-0070-6. Epub 2018 Jan 16.
207 LncRNA-SVUGP2 suppresses progression of hepatocellular carcinoma.Oncotarget. 2017 May 29;8(58):97835-97850. doi: 10.18632/oncotarget.18279. eCollection 2017 Nov 17.
208 Genetic variation of Aflatoxin B1 aldehyde reductase genes (AFAR) in human tumour cells.Cancer Lett. 2008 Dec 8;272(1):160-6. doi: 10.1016/j.canlet.2008.07.013. Epub 2008 Aug 26.
209 Carboxypeptidase A4 promotes proliferation and stem cell characteristics of hepatocellular carcinoma.Int J Exp Pathol. 2019 Apr;100(2):133-138. doi: 10.1111/iep.12315. Epub 2019 May 6.
210 Dopamine-induced SULT1A3/4 promotes EMT and cancer stemness in hepatocellular carcinoma.Tumour Biol. 2017 Oct;39(10):1010428317719272. doi: 10.1177/1010428317719272.
211 Impaired phosphorylation and ubiquitination by p70 S6 kinase (p70S6K) and Smad ubiquitination regulatory factor 1 (Smurf1) promote tribbles homolog 2 (TRIB2) stability and carcinogenic property in liver cancer.J Biol Chem. 2013 Nov 22;288(47):33667-33681. doi: 10.1074/jbc.M113.503292. Epub 2013 Oct 2.
212 AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.Acta Biomater. 2019 Jun;91:195-208. doi: 10.1016/j.actbio.2019.04.053. Epub 2019 Apr 26.
213 DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival.J Biol Chem. 2011 Sep 2;286(35):30706-30713. doi: 10.1074/jbc.M111.229831. Epub 2011 Jul 7.
214 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization.Clin Transl Oncol. 2020 Jan;22(1):70-80. doi: 10.1007/s12094-019-02146-3. Epub 2019 Jun 10.
215 Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA.Oncogene. 2017 Dec 14;36(50):6895-6905. doi: 10.1038/onc.2017.291. Epub 2017 Aug 28.
216 Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells.J Pharmacol Exp Ther. 2017 Jun;361(3):386-397. doi: 10.1124/jpet.116.239707. Epub 2017 Apr 7.
217 MAT2B mediates invasion and metastasis by regulating EGFR signaling pathway in hepatocellular carcinoma.Clin Exp Med. 2019 Nov;19(4):535-546. doi: 10.1007/s10238-019-00579-2. Epub 2019 Sep 6.
218 Point-of-Care Assay of Alkaline Phosphatase Enzymatic Activity Using a Thermometer or Temperature Discoloration Sticker as Readout.Anal Chem. 2019 Jun 18;91(12):7943-7949. doi: 10.1021/acs.analchem.9b01883. Epub 2019 May 31.
219 HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression.Cell Rep. 2014 Sep 25;8(6):1930-1942. doi: 10.1016/j.celrep.2014.08.028. Epub 2014 Sep 18.
220 OY-TES-1 may regulate the malignant behavior of liver cancer via NANOG, CD9, CCND2 and CDCA3: a bioinformatic analysis combine with RNAi and oligonucleotide microarray.Oncol Rep. 2015 Apr;33(4):1965-75. doi: 10.3892/or.2015.3792. Epub 2015 Feb 10.
221 MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA.Biochem Biophys Res Commun. 2014 Feb 7;444(2):270-5. doi: 10.1016/j.bbrc.2014.01.051. Epub 2014 Jan 22.
222 Integrative transcriptome analysis of liver cancer profiles identifies upstream regulators and clinical significance of ACSM3 gene expression.Cell Oncol (Dordr). 2017 Jun;40(3):219-233. doi: 10.1007/s13402-017-0321-0. Epub 2017 Apr 7.
223 ARP3 promotes tumor metastasis and predicts a poor prognosis in hepatocellular carcinoma.Pathol Res Pract. 2018 Sep;214(9):1356-1361. doi: 10.1016/j.prp.2018.05.028. Epub 2018 Jun 7.
224 XB130 Knockdown Inhibits the Proliferation, Invasiveness, and Metastasis of Hepatocellular Carcinoma Cells and Sensitizes them to TRAIL-Induced Apoptosis.Chin Med J (Engl). 2018 Oct 5;131(19):2320-2331. doi: 10.4103/0366-6999.241800.
225 Protective effect of RIP and c-FLIP in preventing liver cancer cell apoptosis induced by TRAIL.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6519-25. eCollection 2015.
226 Distinctive pattern of AHNAK methylation level in peripheral blood mononuclear cells and the association with HBV-related liver diseases.Cancer Med. 2018 Oct;7(10):5178-5186. doi: 10.1002/cam4.1778. Epub 2018 Sep 27.
227 A-kinase anchoring protein 12 is downregulated in human hepatocellular carcinoma and its deficiency in mice aggravates thioacetamide-induced liver injury.Oncol Lett. 2018 Nov;16(5):5907-5915. doi: 10.3892/ol.2018.9396. Epub 2018 Sep 4.
228 Design Graph Theoretical Analysis and In Silico Modeling of Dunaliella Bardawil Biomass Encapsulated N-Succinyl Chitosan Nanoparticles for Enhanced Anticancer Activity.Anticancer Agents Med Chem. 2018;18(13):1900-1918. doi: 10.2174/1871520618666180628155223.
229 Metabolic control of PPAR activity by aldehyde dehydrogenase regulates invasive cell behavior and predicts survival in hepatocellular and renal clear cell carcinoma.BMC Cancer. 2018 Nov 28;18(1):1180. doi: 10.1186/s12885-018-5061-7.
230 Heat shock exerts anticancer effects on liver cancer via autophagic degradation of aquaporin 5.Int J Oncol. 2017 May;50(5):1857-1867. doi: 10.3892/ijo.2017.3940. Epub 2017 Mar 29.
231 Label-free cytosensing of cancer cells based on the interaction between protein and an electron-transfer carbohydrate-mimetic peptide.Anal Chim Acta. 2018 Dec 21;1040:166-176. doi: 10.1016/j.aca.2018.08.025. Epub 2018 Aug 16.
232 Reciprocal regulation between TrCP and Smurf1 suppresses proliferative capacity of liver cancer cells.J Cell Physiol. 2017 Dec;232(12):3347-3359. doi: 10.1002/jcp.25780. Epub 2017 Mar 6.
233 Dynamic network biomarker indicates pulmonary metastasis at the tipping point of hepatocellular carcinoma.Nat Commun. 2018 Feb 14;9(1):678. doi: 10.1038/s41467-018-03024-2.
234 Targeting CAND1 promotes caspase-8/RIP1-dependent apoptosis in liver cancer cells.Am J Transl Res. 2018 May 15;10(5):1357-1372. eCollection 2018.
235 miR-449a promotes liver cancer cell apoptosis by downregulation of Calpain 6 and POU2F1.Oncotarget. 2016 Mar 22;7(12):13491-501. doi: 10.18632/oncotarget.4821.
236 HMDB and 5-AzadC Combination Reverses Tumor Suppressor CCAAT/Enhancer-Binding Protein Delta to Strengthen the Death of Liver Cancer Cells.Mol Cancer Ther. 2015 Nov;14(11):2623-33. doi: 10.1158/1535-7163.MCT-15-0025. Epub 2015 Sep 10.
237 Ceramide synthase-4 orchestrates the cell proliferation and tumor growth of liver cancer in vitro and in vivo through the nuclear factor-B signaling pathway.Oncol Lett. 2017 Aug;14(2):1477-1483. doi: 10.3892/ol.2017.6365. Epub 2017 Jun 9.
238 Inducible factors for cancer-associated fibroblasts in liver cancer versus myofibroblasts in inflammatory liver disease.Histol Histopathol. 2016 Feb;31(2):141-8. doi: 10.14670/HH-11-668. Epub 2015 Sep 23.
239 Cyclic adenosine monophosphate response element-binding protein transcriptionally regulates CHCHD2 associated with the molecular pathogenesis of hepatocellular carcinoma.Mol Med Rep. 2015 Jun;11(6):4053-62. doi: 10.3892/mmr.2015.3256. Epub 2015 Jan 26.
240 CISD2 associated with proliferation indicates negative prognosis in patients with hepatocellular carcinoma.Int J Clin Exp Pathol. 2015 Oct 1;8(10):13725-38. eCollection 2015.
241 CLDN3 inhibits cancer aggressiveness via Wnt-EMT signaling and is a potential prognostic biomarker for hepatocellular carcinoma.Oncotarget. 2014 Sep 15;5(17):7663-76. doi: 10.18632/oncotarget.2288.
242 Dectin-1 Regulates Hepatic Fibrosis and Hepatocarcinogenesis by Suppressing TLR4 Signaling Pathways.Cell Rep. 2015 Dec 1;13(9):1909-1921. doi: 10.1016/j.celrep.2015.10.058. Epub 2015 Nov 19.
243 SiRNA-Mediated Down-Regulation of CLIC4 Gene Inhibits Cell Proliferation and Accelerates Cell Apoptosis of Mouse Liver Cancer Hca-F and Hca-P Cells.J Cell Biochem. 2018 Jan;119(1):659-668. doi: 10.1002/jcb.26229. Epub 2017 Jul 31.
244 Investigation of the role of cullin 4A overexpression in human liver cancer.Mol Med Rep. 2018 Sep;18(3):2531-2540. doi: 10.3892/mmr.2018.9233. Epub 2018 Jun 29.
245 Reduced expression of DACT2 promotes hepatocellular carcinoma progression: involvement of methylation-mediated gene silencing.World J Surg Oncol. 2013 Mar 7;11:57. doi: 10.1186/1477-7819-11-57.
246 DDX3, a potential target for cancer treatment.Mol Cancer. 2015 Nov 5;14:188. doi: 10.1186/s12943-015-0461-7.
247 -defensin 1 expression in HCV infected liver/liver cancer: an important role in protecting HCV progression and liver cancer development.Sci Rep. 2017 Oct 17;7(1):13404. doi: 10.1038/s41598-017-13332-0.
248 DEPDC7 inhibits cell proliferation, migration and invasion in hepatoma cells.Oncol Lett. 2017 Dec;14(6):7332-7338. doi: 10.3892/ol.2017.7128. Epub 2017 Oct 3.
249 Establishment of a novel hepatic steatosis cell model by Cas9/sgRNA-mediated DGK gene knockout.Mol Med Rep. 2018 Feb;17(2):2169-2176. doi: 10.3892/mmr.2017.8140. Epub 2017 Nov 22.
250 Plasma glutamate carboxypeptidase is a negative regulator in liver cancer metastasis.Oncotarget. 2016 Nov 29;7(48):79774-79786. doi: 10.18632/oncotarget.12967.
251 Hepatitis B core protein promotes liver cancer metastasis through miR-382-5p/DLC-1 axis.Biochim Biophys Acta Mol Cell Res. 2018 Jan;1865(1):1-11. doi: 10.1016/j.bbamcr.2017.09.020. Epub 2017 Oct 3.
252 Novel 1,4-dihydropyridine induces apoptosis in human cancer cells through overexpression of Sirtuin1.Apoptosis. 2018 Oct;23(9-10):532-553. doi: 10.1007/s10495-018-1483-6.
253 MicroRNA-302a/d inhibits the self-renewal capability and cell cycle entry of liver cancer stem cells by targeting the E2F7/AKT axis.J Exp Clin Cancer Res. 2018 Oct 16;37(1):252. doi: 10.1186/s13046-018-0927-8.
254 Attenuation of enoyl coenzyme A hydratase 1 expression in colorectal cancer cells using small interfering RNA inhibits cell proliferation and migration.Mol Med Rep. 2015 Jul;12(1):470-4. doi: 10.3892/mmr.2015.3418. Epub 2015 Mar 4.
255 High EIF2B5 mRNA expression and its prognostic significance in liver cancer: a study based on the TCGA and GEO database.Cancer Manag Res. 2018 Nov 20;10:6003-6014. doi: 10.2147/CMAR.S185459. eCollection 2018.
256 miRNA-346 promotes proliferation, migration and invasion in liver cancer.Oncol Lett. 2017 Sep;14(3):3255-3260. doi: 10.3892/ol.2017.6561. Epub 2017 Jul 8.
257 Genetic risk analysis for an individual according to the theory of programmed onset, illustrated by lung and liver cancers.Gene. 2018 Oct 5;673:107-111. doi: 10.1016/j.gene.2018.06.044. Epub 2018 Jun 15.
258 Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.Cell Physiol Biochem. 2017;41(6):2289-2306. doi: 10.1159/000475648. Epub 2017 Apr 26.
259 NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis.Cancer Sci. 2017 Jan;108(1):12-22. doi: 10.1111/cas.13117.
260 Follistatin-like protein 5 inhibits hepatocellular carcinoma progression by inducing caspase-dependent apoptosis and regulating Bcl-2 family proteins.J Cell Mol Med. 2018 Dec;22(12):6190-6201. doi: 10.1111/jcmm.13906. Epub 2018 Sep 25.
261 GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.Pharmacogenomics. 2016 Mar;17(4):353-66. doi: 10.2217/pgs.15.179. Epub 2016 Feb 12.
262 LncGPR107 drives the self-renewal of liver tumor initiating cells and liver tumorigenesis through GPR107-dependent manner.J Exp Clin Cancer Res. 2018 Jun 20;37(1):121. doi: 10.1186/s13046-018-0794-3.
263 Loss of NR2E3 represses AHR by LSD1 reprogramming, is associated with poor prognosis in liver cancer.Sci Rep. 2017 Sep 6;7(1):10662. doi: 10.1038/s41598-017-11106-2.
264 Phase angle as a severity indicator for liver diseases.Nutrition. 2020 Feb;70:110607. doi: 10.1016/j.nut.2019.110607. Epub 2019 Oct 11.
265 Comprehensive molecular profiling of the B7 family in gastrointestinal cancer.Cell Prolif. 2018 Oct;51(5):e12468. doi: 10.1111/cpr.12468. Epub 2018 Jul 12.
266 Suppression of Lefty expression in induced pluripotent cancer cells.FASEB J. 2013 Jun;27(6):2165-74. doi: 10.1096/fj.12-221432. Epub 2013 Feb 13.
267 Homeobox containing1 inhibits liver cancer progression by promoting autophagy as well as inhibiting stemness and immune escape.Oncol Rep. 2018 Sep;40(3):1657-1665. doi: 10.3892/or.2018.6551. Epub 2018 Jul 10.
268 Abnormal expression of HMGB-3 is significantly associated with malignant transformation of hepatocytes.World J Gastroenterol. 2018 Aug 28;24(32):3650-3662. doi: 10.3748/wjg.v24.i32.3650.
269 Fenretinide inhibits the proliferation and migration of human liver cancer HepG2 cells by downregulating the activation of myosin light chain kinase through the p38MAPK signaling pathway.Oncol Rep. 2018 Jul;40(1):518-526. doi: 10.3892/or.2018.6436. Epub 2018 May 16.
270 Genomic copy number alterations with transcriptional deregulation at 6p identify an aggressive HCC phenotype.Carcinogenesis. 2013 Jul;34(7):1543-50. doi: 10.1093/carcin/bgt095. Epub 2013 Mar 18.
271 Transcriptional regulation of IER5 in response to radiation in HepG2.Cancer Gene Ther. 2016 Feb-Mar;23(2-3):61-5. doi: 10.1038/cgt.2016.1. Epub 2016 Feb 26.
272 JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity.Cancer Res. 2017 Oct 1;77(19):5287-5300. doi: 10.1158/0008-5472.CAN-17-0229. Epub 2017 Aug 3.
273 Suppressed Krppellike factor 17 expression induces tumor proliferation, metastasis and a poor prognosis in papillary thyroid carcinoma.Mol Med Rep. 2014 Oct;10(4):2087-92. doi: 10.3892/mmr.2014.2429. Epub 2014 Jul 29.
274 Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.Biomacromolecules. 2018 Jun 11;19(6):2330-2339. doi: 10.1021/acs.biomac.8b00358. Epub 2018 May 29.
275 Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.Gastroenterology. 2018 Aug;155(2):557-571.e14. doi: 10.1053/j.gastro.2018.04.032. Epub 2018 May 5.
276 LncMAPK6 drives MAPK6 expression and liver TIC self-renewal.J Exp Clin Cancer Res. 2018 May 15;37(1):105. doi: 10.1186/s13046-018-0770-y.
277 Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma.Oncotarget. 2015 Sep 15;6(27):23807-19. doi: 10.18632/oncotarget.4278.
278 Increased mediator complex subunit 15 expression is associated with poor prognosis in hepatocellular carcinoma.Oncol Lett. 2018 Apr;15(4):4303-4313. doi: 10.3892/ol.2018.7820. Epub 2018 Jan 18.
279 NASP antagonize chromatin accessibility through maintaining histone H3K9me1 in hepatocellular carcinoma.Biochim Biophys Acta Mol Basis Dis. 2018 Oct;1864(10):3438-3448. doi: 10.1016/j.bbadis.2018.07.033. Epub 2018 Aug 1.
280 Imbalanced expression pattern of steroid receptor coactivator-1 and -3 in liver cancer compared with normal liver: An immunohistochemical study with tissue microarray.Oncol Lett. 2018 Nov;16(5):6339-6348. doi: 10.3892/ol.2018.9443. Epub 2018 Sep 17.
281 Hepatocellular Carcinoma Outcome Is Predicted by Expression of Neuronal Calcium Sensor 1.Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):1091-1100. doi: 10.1158/1055-9965.EPI-18-0167. Epub 2018 May 22.
282 Integrated Genomic Comparison of Mouse Models Reveals Their Clinical Resemblance to Human Liver Cancer.Mol Cancer Res. 2018 Nov;16(11):1713-1723. doi: 10.1158/1541-7786.MCR-18-0313. Epub 2018 Aug 6.
283 NKD1 marks intestinal and liver tumors linked to aberrant Wnt signaling.Cell Signal. 2015 Feb;27(2):245-56. doi: 10.1016/j.cellsig.2014.11.008. Epub 2014 Nov 14.
284 Methylation of nucleolar and coiled-body phosphoprotein1 is associated with the mechanism of tumorigenesis in hepatocellular carcinoma.Oncol Rep. 2013 Nov;30(5):2220-8. doi: 10.3892/or.2013.2676. Epub 2013 Aug 20.
285 NUMB phosphorylation destabilizes p53 and promotes self-renewal of tumor-initiating cells by a NANOG-dependent mechanism in liver cancer.Hepatology. 2015 Nov;62(5):1466-79. doi: 10.1002/hep.27987. Epub 2015 Aug 28.
286 Transcriptome Analysis Uncovers a Growth-Promoting Activity of Orosomucoid-1 on Hepatocytes.EBioMedicine. 2017 Oct;24:257-266. doi: 10.1016/j.ebiom.2017.09.008. Epub 2017 Sep 12.
287 NOR1 promotes hepatocellular carcinoma cell proliferation and migration through modulating the Notch signaling pathway.Exp Cell Res. 2017 Mar 15;352(2):375-381. doi: 10.1016/j.yexcr.2017.02.032. Epub 2017 Feb 21.
288 Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis.Hepatology. 2017 Feb;65(2):515-528. doi: 10.1002/hep.28887. Epub 2016 Nov 29.
289 Silencing HIWI suppresses the growth, invasion and migration of glioma cells.Int J Oncol. 2014 Dec;45(6):2385-92. doi: 10.3892/ijo.2014.2673. Epub 2014 Sep 25.
290 Plectin deficiency in liver cancer cells promotes cell migration and sensitivity to sorafenib treatment.Cell Adh Migr. 2018 Jan 2;12(1):19-27. doi: 10.1080/19336918.2017.1288789. Epub 2017 Feb 17.
291 Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair.Cell. 2016 Jan 28;164(3):538-49. doi: 10.1016/j.cell.2015.12.050. Epub 2016 Jan 21.
292 Chitosan-coated doxorubicin nano-particles drug delivery system inhibits cell growth of liver cancer via p53/PRC1 pathway.Biochem Biophys Res Commun. 2018 Jan 1;495(1):414-420. doi: 10.1016/j.bbrc.2017.10.156. Epub 2017 Oct 31.
293 The effect of CXCL9 on the invasion ability of hepatocellular carcinoma through up-regulation of PREX2.J Mol Histol. 2014 Dec;45(6):689-96. doi: 10.1007/s10735-014-9593-0. Epub 2014 Aug 24.
294 The role of PRRX1 in the apoptosis of A549 cells induced by cisplatin.Am J Transl Res. 2017 Feb 15;9(2):396-402. eCollection 2017.
295 POH1 deubiquitylates and stabilizes E2F1 to promote tumour formation.Nat Commun. 2015 Oct 29;6:8704. doi: 10.1038/ncomms9704.
296 Survival and inflammation promotion effect of PTPRO in fulminant hepatitis is associated with NF-B activation.J Immunol. 2014 Nov 15;193(10):5161-70. doi: 10.4049/jimmunol.1303354. Epub 2014 Oct 22.
297 Mice lacking RAP1 show early onset and higher rates of DEN-induced hepatocellular carcinomas in female mice.PLoS One. 2018 Oct 11;13(10):e0204909. doi: 10.1371/journal.pone.0204909. eCollection 2018.
298 Inhibition of RAD54B suppresses proliferation and promotes apoptosis in hepatoma cells.Oncol Rep. 2018 Sep;40(3):1233-1242. doi: 10.3892/or.2018.6522. Epub 2018 Jun 25.
299 RAMP3 is a prognostic indicator of liver cancer and might reduce the adverse effect of TP53 mutation on survival.Future Oncol. 2018 Oct;14(25):2615-2625. doi: 10.2217/fon-2018-0296. Epub 2018 Jun 8.
300 The caspase-3/p120 RasGAP stress-sensing module reduces liver cancer incidence but does not affect overall survival in gamma-irradiated and carcinogen-treated mice.Mol Carcinog. 2017 Jun;56(6):1680-1684. doi: 10.1002/mc.22624. Epub 2017 Feb 16.
301 RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.J Exp Clin Cancer Res. 2018 Sep 3;37(1):212. doi: 10.1186/s13046-018-0852-x.
302 Induction of autophagy and senescence by knockdown of ROC1 E3 ubiquitin ligase to suppress the growth of liver cancer cells.Cell Death Differ. 2013 Feb;20(2):235-47. doi: 10.1038/cdd.2012.113. Epub 2012 Aug 31.
303 Upregulation of RECQL4 expression predicts poor prognosis in hepatocellular carcinoma.Oncol Lett. 2018 Apr;15(4):4248-4254. doi: 10.3892/ol.2018.7860. Epub 2018 Jan 25.
304 HULC cooperates with MALAT1 to aggravate liver cancer stem cells growth through telomere repeat-binding factor 2.Sci Rep. 2016 Oct 26;6:36045. doi: 10.1038/srep36045.
305 Oncogene RPA1 promotes proliferation of hepatocellular carcinoma via CDK4/Cyclin-D pathway.Biochem Biophys Res Commun. 2018 Apr 6;498(3):424-430. doi: 10.1016/j.bbrc.2018.02.167. Epub 2018 Mar 15.
306 R-spondin 2 promotes proliferation and migration via the Wnt/-catenin pathway in human hepatocellular carcinoma.Oncol Lett. 2017 Aug;14(2):1757-1765. doi: 10.3892/ol.2017.6339. Epub 2017 Jun 7.
307 Identification of natural splice variants of SAMHD1 in virus-infected HCC.Oncol Rep. 2014 Feb;31(2):687-92. doi: 10.3892/or.2013.2895. Epub 2013 Dec 5.
308 Ultrasensitive Detection of Serum MicroRNA Using Branched DNA-Based SERS Platform Combining Simultaneous Detection of -Fetoprotein for Early Diagnosis of Liver Cancer.ACS Appl Mater Interfaces. 2018 Oct 17;10(41):34869-34877. doi: 10.1021/acsami.8b10252. Epub 2018 Oct 5.
309 Promoter methylation assay of SASH1 gene in hepatocellular carcinoma.J BUON. 2014 Oct-Dec;19(4):1041-7.
310 Cell cycle-dependent degradation of the methyltransferase SETD3 attenuates cell proliferation and liver tumorigenesis.J Biol Chem. 2017 Jun 2;292(22):9022-9033. doi: 10.1074/jbc.M117.778001. Epub 2017 Apr 25.
311 SF3B4 as an early-stage diagnostic marker and driver of hepatocellular carcinoma.BMB Rep. 2018 Feb;51(2):57-58. doi: 10.5483/bmbrep.2018.51.2.021.
312 Facilitation of liver cancer SMCC7721 cell aging by sirtuin 4 via inhibiting JAK2/STAT3 signal pathway.Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1248-1253.
313 SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma.RNA Biol. 2018;15(10):1364-1375. doi: 10.1080/15476286.2018.1534525. Epub 2018 Oct 25.
314 Downregulation of sorting nexin 10 is associated with overexpression of miR-30d during liver cancer progression in rats.Tumour Biol. 2017 Apr;39(4):1010428317695932. doi: 10.1177/1010428317695932.
315 RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.Hepatology. 2018 Jun;67(6):2254-2270. doi: 10.1002/hep.29683. Epub 2018 Apr 19.
316 Speckle-type POZ protein is negatively associated with malignancies and inhibits cell proliferation and migration in liver cancer.Tumour Biol. 2015 Dec;36(12):9753-61. doi: 10.1007/s13277-015-3753-z. Epub 2015 Jul 10.
317 SPRTN protease and checkpoint kinase 1 cross-activation loop safeguards DNA replication.Nat Commun. 2019 Jul 17;10(1):3142. doi: 10.1038/s41467-019-11095-y.
318 [ARTICLE WITHDRAWN] Downregulation of SRC Kinase Signaling Inhibitor 1 (SRCIN1) Expression by MicroRNA-32 Promotes Proliferation and Epithelial-Mesenchymal Transition in Human Liver Cancer Cells.Oncol Res. 2018 May 7;26(4):573-579. doi: 10.3727/096504017X14954923820137. Epub 2017 May 22.
319 The Down-Regulation of SUZ12 Accelerates the Migration and Invasion of Liver Cancer Cells via Activating ERK1/2 Pathway.J Cancer. 2019 Feb 23;10(6):1375-1384. doi: 10.7150/jca.29932. eCollection 2019.
320 C8orf4 negatively regulates self-renewal of liver cancer stem cells via suppression of NOTCH2 signalling.Nat Commun. 2015 May 19;6:7122. doi: 10.1038/ncomms8122.
321 Tex10 is upregulated and promotes cancer stem cell properties and chemoresistance in hepatocellular carcinoma.Cell Cycle. 2018;17(11):1310-1318. doi: 10.1080/15384101.2018.1480208. Epub 2018 Jul 25.
322 LncRNA DILC participates in rheumatoid arthritis by inducing apoptosis of fibroblast-like synoviocytes and down-regulating IL-6.Biosci Rep. 2019 May 2;39(5):BSR20182374. doi: 10.1042/BSR20182374. Print 2019 May 31.
323 CD133-induced TM4SF5 expression promotes sphere growth via recruitment and blocking of protein tyrosine phosphatase receptor type F (PTPRF).Cancer Lett. 2018 Dec 1;438:219-231. doi: 10.1016/j.canlet.2018.09.009. Epub 2018 Sep 11.
324 MiR-155 targets TP53INP1 to regulate liver cancer stem cell acquisition and self-renewal.FEBS Lett. 2015 Feb 13;589(4):500-6. doi: 10.1016/j.febslet.2015.01.009. Epub 2015 Jan 17.
325 Effect on the liver cancer cell invasion ability by studying the associations between autophagy and TRAP1 expression.Oncol Lett. 2018 Jul;16(1):991-997. doi: 10.3892/ol.2018.8774. Epub 2018 May 22.
326 A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling.Cell Death Dis. 2018 May 1;9(5):443. doi: 10.1038/s41419-018-0467-3.
327 CD5L is upregulated in hepatocellular carcinoma and promotes liver cancer cell proliferation and antiapoptotic responses by binding to HSPA5 (GRP78).FASEB J. 2018 Jul;32(7):3878-3891. doi: 10.1096/fj.201700941RR. Epub 2018 Feb 20.
328 Overexpression of CMTM7 inhibits cell growth and migration in liver cancer.Kaohsiung J Med Sci. 2019 Jun;35(6):332-340. doi: 10.1002/kjm2.12058. Epub 2019 Mar 23.
329 Dishevelled 1, a pivotal positive regulator of the Wnt signalling pathway, mediates 5-fluorouracil resistance in HepG2 cells.Artif Cells Nanomed Biotechnol. 2018;46(sup2):192-200. doi: 10.1080/21691401.2018.1453827. Epub 2018 Mar 27.
330 Elovl6 is a negative clinical predictor for liver cancer and knockdown of Elovl6 reduces murine liver cancer progression.Sci Rep. 2018 Apr 26;8(1):6586. doi: 10.1038/s41598-018-24633-3.
331 The FHL2 regulation in the transcriptional circuitry of human cancers.Gene. 2015 Nov 1;572(1):1-7. doi: 10.1016/j.gene.2015.07.043. Epub 2015 Jul 26.
332 LncFZD6 initiates Wnt/-catenin and liver TIC self-renewal through BRG1-mediated FZD6 transcriptional activation.Oncogene. 2018 Jun;37(23):3098-3112. doi: 10.1038/s41388-018-0203-6. Epub 2018 Mar 14.
333 GDF11/BMP11 as a novel tumor marker for liver cancer.Exp Ther Med. 2018 Apr;15(4):3495-3500. doi: 10.3892/etm.2018.5861. Epub 2018 Feb 12.
334 Hepatitis B virus upregulates GP73 expression by activating the HIF-2 signaling pathway.Oncol Lett. 2018 Apr;15(4):5264-5270. doi: 10.3892/ol.2018.7955. Epub 2018 Feb 5.
335 GTSF1 gene may serve as a novel potential diagnostic biomarker for liver cancer.Oncol Lett. 2018 Mar;15(3):3133-3140. doi: 10.3892/ol.2017.7695. Epub 2017 Dec 27.
336 The role of kinesin KIF18A in the invasion and metastasis of hepatocellular carcinoma.World J Surg Oncol. 2018 Feb 21;16(1):36. doi: 10.1186/s12957-018-1342-5.
337 MORC2, a novel oncogene, is upregulated in liver cancer and contributes to proliferation, metastasis and chemoresistance.Int J Oncol. 2018 Jul;53(1):59-72. doi: 10.3892/ijo.2018.4333. Epub 2018 Mar 27.
338 Overexpression of RHEB is associated with metastasis and poor prognosis in hepatocellular carcinoma.Oncol Lett. 2018 Mar;15(3):3838-3845. doi: 10.3892/ol.2018.7759. Epub 2018 Jan 10.
339 HIF-1-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.Cancer Lett. 2019 Sep 28;460:96-107. doi: 10.1016/j.canlet.2019.06.016. Epub 2019 Jun 24.
340 Analysis of long non-coding RNA (lncRNA) expression in hepatitis B patients.Bosn J Basic Med Sci. 2018 May 20;18(2):150-161. doi: 10.17305/bjbms.2018.2800.
341 Sensitive ADAR editing reporter in cancer cells enables high-throughput screening of small molecule libraries.Nucleic Acids Res. 2019 Feb 28;47(4):e22. doi: 10.1093/nar/gky1228.
342 Molecular cloning and characterization of a RING-H2 finger protein, ANAPC11, the human homolog of yeast Apc11p.J Cell Biochem. 2001 Aug 1-9;83(2):249-58. doi: 10.1002/jcb.1217.
343 Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.Neoplasia. 2009 Feb;11(2):196-206. doi: 10.1593/neo.08734.
344 Argininosuccinate lyase is a potential therapeutic target in breast cancer.Oncol Rep. 2015 Dec;34(6):3131-9. doi: 10.3892/or.2015.4280. Epub 2015 Sep 16.
345 SP1 is required for basal activation and chromatin accessibility of CD151 promoter in liver cancer cells.Biochem Biophys Res Commun. 2010 Mar 5;393(2):291-6. doi: 10.1016/j.bbrc.2010.01.127. Epub 2010 Feb 10.
346 The Munich-Transarterial Chemoembolisation Score Holds Superior Prognostic Capacities Compared to TACE-Tailored Modifications of 9 Established Staging Systems for Hepatocellular Carcinoma.Digestion. 2019;100(1):15-26. doi: 10.1159/000493136. Epub 2018 Oct 3.
347 MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma.PLoS One. 2012;7(11):e48958. doi: 10.1371/journal.pone.0048958. Epub 2012 Nov 7.
348 Human CRYL1, a novel enzyme-crystallin overexpressed in liver and kidney and downregulated in 58% of liver cancer tissues from 60 Chinese patients, and four new homologs from other mammalians.Gene. 2003 Jan 2;302(1-2):103-13. doi: 10.1016/s0378-1119(02)01095-8.
349 Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis.Hepatology. 2009 Feb;49(2):513-22. doi: 10.1002/hep.22698.
350 ARHI, as a novel suppressor of cell growth and downregulated in human hepatocellular carcinoma, could contribute to hepatocarcinogenesis.Mol Carcinog. 2009 Feb;48(2):130-40. doi: 10.1002/mc.20461.
351 Serum starvation induces DRAM expression in liver cancer cells via histone modifications within its promoter locus.PLoS One. 2012;7(12):e50502. doi: 10.1371/journal.pone.0050502. Epub 2012 Dec 12.
352 The role of CUGBP1 in age-dependent changes of liver functions.Ageing Res Rev. 2012 Sep;11(4):442-9. doi: 10.1016/j.arr.2012.02.007. Epub 2012 Mar 14.
353 Antisense oligonucleotide Elk-1 suppresses the tumorigenicity of human hepatocellular carcinoma cells.Cell Biol Int. 2008 Feb;32(2):210-6. doi: 10.1016/j.cellbi.2007.08.027. Epub 2007 Sep 7.
354 High FOXK1 expression correlates with poor outcomes in hepatocellular carcinoma and regulates stemness of hepatocellular carcinoma cells.Life Sci. 2019 Jul 1;228:128-134. doi: 10.1016/j.lfs.2019.04.068. Epub 2019 May 1.
355 Far upstream element-binding protein 1 facilitates hepatocellular carcinoma invasion and metastasis.Carcinogenesis. 2020 Jul 14;41(7):950-960. doi: 10.1093/carcin/bgz171.
356 Predominant modifier of extreme liver cancer susceptibility in C57BR/cdJ female mice localized to 6 Mb on chromosome 17.Carcinogenesis. 2009 May;30(5):879-85. doi: 10.1093/carcin/bgp054. Epub 2009 Mar 2.
357 Expression and prognostic value of ING3 in human primary hepatocellular carcinoma.Exp Biol Med (Maywood). 2012 Apr;237(4):352-61. doi: 10.1258/ebm.2011.011346.
358 LDB2 inhibits proliferation and migration in liver cancer cells by abrogating HEY1 expression.Oncotarget. 2017 Oct 10;8(55):94440-94449. doi: 10.18632/oncotarget.21772. eCollection 2017 Nov 7.
359 Circulating Lamin B1 (LMNB1) biomarker detects early stages of liver cancer in patients.J Proteome Res. 2010 Jan;9(1):70-8. doi: 10.1021/pr9002118.
360 Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.Gastroenterology. 2012 Dec;143(6):1660-1669.e7. doi: 10.1053/j.gastro.2012.09.002. Epub 2012 Sep 11.
361 Transforming Growth Factor TGF Increases Levels of Microtubule-Associated Protein MAP1S and Autophagy Flux in Pancreatic Ductal Adenocarcinomas.PLoS One. 2015 Nov 16;10(11):e0143150. doi: 10.1371/journal.pone.0143150. eCollection 2015.
362 Expressions of Carbohydrate Response Element Binding Protein and Glucose Transporters in Liver Cancer and Clinical Significance.Pathol Oncol Res. 2020 Apr;26(2):1331-1340. doi: 10.1007/s12253-019-00708-y. Epub 2019 Aug 12.
363 Phenotypic and functional differences between human liver cancer endothelial cells and liver sinusoidal endothelial cells.J Vasc Res. 2008;45(1):78-86. doi: 10.1159/000109079. Epub 2007 Sep 27.
364 Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79.Cancer Chemother Pharmacol. 2009 Apr;63(5):769-78. doi: 10.1007/s00280-008-0801-z. Epub 2008 Jul 19.
365 Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma.J Cell Biochem. 2010 Jun 1;110(3):687-96. doi: 10.1002/jcb.22579.
366 The role of 5' untranslated region in translational suppression of OKL38 mRNA in hepatocellular carcinoma.Oncogene. 2007 Feb 22;26(8):1155-65. doi: 10.1038/sj.onc.1209896. Epub 2006 Aug 21.
367 Decreased expression of protocadherin 20 is associated with poor prognosis in hepatocellular carcinoma.Oncotarget. 2017 Jan 10;8(2):3018-3028. doi: 10.18632/oncotarget.13822.
368 Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.Cell Death Dis. 2017 Oct 26;8(10):e3138. doi: 10.1038/cddis.2017.512.
369 Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer.Gastroenterology. 2006 Oct;131(4):1218-27. doi: 10.1053/j.gastro.2006.07.020. Epub 2006 Jul 24.
370 Expression of the prothymosin-a gene as a prognostic factor in lung cancer.Surg Today. 2001;31(10):936-8. doi: 10.1007/s005950170040.
371 Activation of cellular immunity and marked inhibition of liver cancer in a mouse model following gene therapy and tumor expression of GM-SCF, IL-21, and Rae-1.Mol Cancer. 2013 Dec 18;12(1):166. doi: 10.1186/1476-4598-12-166.
372 Prolonged survival of patients with colorectal cancer is associated with a higher regucalcin gene expression: Overexpression of regucalcin suppresses the growth of human colorectal carcinoma cells invitro.Int J Oncol. 2018 Sep;53(3):1313-1322. doi: 10.3892/ijo.2018.4458. Epub 2018 Jun 28.
373 Ribose-5-phosphate isomerase A overexpression promotes liver cancer development in transgenic zebrafish via activation of ERK and -catenin pathways.Carcinogenesis. 2019 May 14;40(3):461-473. doi: 10.1093/carcin/bgy155.
374 Methylation analysis of p16, SLIT2, SCARA5, and Runx3 genes in hepatocellular carcinoma.Medicine (Baltimore). 2017 Oct;96(41):e8279. doi: 10.1097/MD.0000000000008279.
375 Splicing Regulator p54(nrb) /Non-POU Domain-Containing Octamer-Binding Protein Enhances Carcinogenesis Through Oncogenic Isoform Switch of MYC Box-Dependent Interacting Protein 1 in Hepatocellular Carcinoma.Hepatology. 2020 Aug;72(2):548-568. doi: 10.1002/hep.31062. Epub 2020 Mar 25.
376 Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter.Gastroenterology. 2010 May;138(5):1898-908. doi: 10.1053/j.gastro.2009.12.044. Epub 2009 Dec 29.
377 Increased Expression of Serine Hydroxymethyltransferase 2 (SHMT2) is a Negative Prognostic Marker in Patients with Hepatocellular Carcinoma and is Associated with Proliferation of HepG2 Cells.Med Sci Monit. 2019 Aug 5;25:5823-5832. doi: 10.12659/MSM.915754.
378 SP1 plays a pivotal role for basal activity of TIGAR promoter in liver cancer cell lines.Mol Cell Biochem. 2012 Jan;359(1-2):17-23. doi: 10.1007/s11010-011-0993-0. Epub 2011 Jul 15.
379 The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras.Mol Cell. 2012 Mar 9;45(5):610-8. doi: 10.1016/j.molcel.2012.01.006. Epub 2012 Feb 8.
380 Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.Chin J Cancer. 2017 Sep 26;36(1):77. doi: 10.1186/s40880-017-0240-5.
381 TSPY potentiates cell proliferation and tumorigenesis by promoting cell cycle progression in HeLa and NIH3T3 cells.BMC Cancer. 2006 Jun 9;6:154. doi: 10.1186/1471-2407-6-154.
382 Associations between polymorphisms of the ACYP2 gene and Liver cancer risk: A case-control study and meta-analysis.Mol Genet Genomic Med. 2019 Jul;7(7):e00716. doi: 10.1002/mgg3.716. Epub 2019 May 23.
383 Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.Stem Cells. 2015 Feb;33(2):354-66. doi: 10.1002/stem.1850.
384 Down-regulation of ANXA7 decreases metastatic potential of human hepatocellular carcinoma cells in vitro.Biomed Pharmacother. 2013 May;67(4):285-91. doi: 10.1016/j.biopha.2013.02.005. Epub 2013 Feb 27.
385 A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage.Nat Commun. 2014 Oct 9;5:5129. doi: 10.1038/ncomms6129.
386 Regulation of white and brown adipocyte differentiation by RhoGAP DLC1.PLoS One. 2017 Mar 30;12(3):e0174761. doi: 10.1371/journal.pone.0174761. eCollection 2017.
387 Ginsenoside Rg3 inhibits the migration and invasion of liver cancer cells by increasing the protein expression of ARHGAP9.Oncol Lett. 2019 Jan;17(1):965-973. doi: 10.3892/ol.2018.9701. Epub 2018 Nov 15.
388 Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma.Int J Cancer. 2013 May 1;132(9):2217-21. doi: 10.1002/ijc.27900. Epub 2012 Nov 20.
389 Hepatitis B virus-regulated growth of liver cancer cells occurs through the microRNA-340-5p-activating transcription factor 7-heat shock protein A member 1B axis.Cancer Sci. 2019 May;110(5):1633-1643. doi: 10.1111/cas.14004. Epub 2019 Apr 11.
390 miR-221-3p and miR-15b-5p promote cell proliferation and invasion by targeting Axin2 in liver cancer.Oncol Lett. 2019 Dec;18(6):6491-6500. doi: 10.3892/ol.2019.11056. Epub 2019 Nov 5.
391 High Expression B3GAT3 Is Related with Poor Prognosis of Liver Cancer.Open Med (Wars). 2019 Feb 26;14:251-258. doi: 10.1515/med-2019-0020. eCollection 2019.
392 The BRUCE-ATR Signaling Axis Is Required for Accurate DNA Replication and Suppression of Liver Cancer Development.Hepatology. 2019 Jun;69(6):2608-2622. doi: 10.1002/hep.30529. Epub 2019 Mar 13.
393 Silencing of the HCCR2 gene induces apoptosis and suppresses the aggressive phenotype of hepatocellular carcinoma cells in culture.J Gastrointest Surg. 2011 Oct;15(10):1807-13. doi: 10.1007/s11605-011-1633-4. Epub 2011 Jul 28.
394 Silencing of Btbd7 Inhibited Epithelial-Mesenchymal Transition and Chemoresistance in CD133(+) Lung Carcinoma A549 Cells.Oncol Res. 2017 May 24;25(5):819-829. doi: 10.3727/096504016X14772349843854. Epub 2016 Oct 26.
395 Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells.J Exp Clin Cancer Res. 2019 Jun 6;38(1):237. doi: 10.1186/s13046-019-1239-3.
396 Sorafenib-loaded hydroxyethyl starch-TG100-115 micelles for the treatment of liver cancer based on synergistic treatment.Drug Deliv. 2019 Dec;26(1):756-764. doi: 10.1080/10717544.2019.1642418.
397 Double mutant P53 (N340Q/L344R) promotes hepatocarcinogenesis through upregulation of Pim1 mediated by PKM2 and LncRNA CUDR.Oncotarget. 2016 Oct 11;7(41):66525-66539. doi: 10.18632/oncotarget.9089.
398 Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer.Oncotarget. 2016 Nov 15;7(46):75763-75773. doi: 10.18632/oncotarget.12409.
399 Liver cancer: WISP3 suppresses hepatocellular carcinoma progression by negative regulation of -catenin/TCF/LEF signalling.Cell Prolif. 2019 May;52(3):e12583. doi: 10.1111/cpr.12583. Epub 2019 Feb 22.
400 CDCA5, Transcribed by E2F1, Promotes Oncogenesis by Enhancing Cell Proliferation and Inhibiting Apoptosis via the AKT Pathway in Hepatocellular Carcinoma.J Cancer. 2019 Apr 21;10(8):1846-1854. doi: 10.7150/jca.28809. eCollection 2019.
401 RNA Binding Protein CUGBP1 Inhibits Liver Cancer in a Phosphorylation-Dependent Manner.Mol Cell Biol. 2017 Jul 28;37(16):e00128-17. doi: 10.1128/MCB.00128-17. Print 2017 Aug 15.
402 Clinical significance of chromodomain helicase/ATPase DNA binding protein 1-like and human mutL homolog 1 gene expression in cholangiocarcinoma.Oncol Lett. 2018 Sep;16(3):2989-2994. doi: 10.3892/ol.2018.9043. Epub 2018 Jun 28.
403 Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma.J Hepatol. 2015 Nov;63(5):1164-72. doi: 10.1016/j.jhep.2015.06.009. Epub 2015 Jun 18.
404 The study on expression of CIAPIN1 interfering hepatocellular carcinoma cell proliferation and its mechanisms.Eur Rev Med Pharmacol Sci. 2017 Jul;21(13):3054-3060.
405 Cold-inducible RNA-binding protein promotes the development of liver cancer.Cancer Sci. 2015 Apr;106(4):352-8. doi: 10.1111/cas.12611. Epub 2015 Mar 3.
406 Loss of miR-1258 contributes to carcinogenesis and progression of liver cancer through targeting CDC28 protein kinase regulatory subunit 1B.Oncotarget. 2016 Jul 12;7(28):43419-43431. doi: 10.18632/oncotarget.9728.
407 In vivo imaging of leucine aminopeptidase activity in drug-induced liver injury and liver cancer via a near-infrared fluorescent probe.Chem Sci. 2017 May 1;8(5):3479-3483. doi: 10.1039/c6sc05712h. Epub 2017 Mar 2.
408 CPSF7 regulates liver cancer growth and metastasis by facilitating WWP2-FL and targeting the WWP2/PTEN/AKT signaling pathway.Biochim Biophys Acta Mol Cell Res. 2020 Feb;1867(2):118624. doi: 10.1016/j.bbamcr.2019.118624. Epub 2019 Dec 12.
409 Rhesus monkey model of liver disease reflecting clinical disease progression and hepatic gene expression analysis.Sci Rep. 2015 Oct 7;5:15019. doi: 10.1038/srep15019.
410 Cytoglobin ameliorates the stemness of hepatocellular carcinoma via coupling oxidative-nitrosative stress signals.Mol Carcinog. 2019 Mar;58(3):334-343. doi: 10.1002/mc.22931. Epub 2018 Dec 4.
411 High GSTP1 inhibits cell proliferation by reducing Akt phosphorylation and is associated with a better prognosis in hepatocellular carcinoma.Oncotarget. 2017 Dec 19;9(10):8957-8971. doi: 10.18632/oncotarget.23420. eCollection 2018 Feb 6.
412 Cloning and characterization of F-LANa, upregulated in human liver cancer.Biochem Biophys Res Commun. 2001 Aug 17;286(2):394-400. doi: 10.1006/bbrc.2001.5390.
413 Clinical significance of aberrant DEUP1 promoter methylation in hepatocellular carcinoma.Oncol Lett. 2019 Aug;18(2):1356-1364. doi: 10.3892/ol.2019.10421. Epub 2019 May 30.
414 AGXT2L1 is down-regulated in heptocellular carcinoma and associated with abnormal lipogenesis.J Clin Pathol. 2016 Mar;69(3):215-20. doi: 10.1136/jclinpath-2015-203042. Epub 2015 Aug 20.
415 Identification of factors interacting with hMSH2 in the fetal liver utilizing the yeast two-hybrid system. In vivo interaction through the C-terminal domains of hEXO1 and hMSH2 and comparative expression analysis.Mutat Res. 2000 Jun 30;460(1):41-52. doi: 10.1016/s0921-8777(00)00012-4.
416 Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability.Hum Mol Genet. 2001 Aug 15;10(17):1741-52. doi: 10.1093/hmg/10.17.1741.
417 FAM83H is involved in the progression of hepatocellular carcinoma and is regulated by MYC.Sci Rep. 2017 Jun 12;7(1):3274. doi: 10.1038/s41598-017-03639-3.
418 ProstaglandinE2 promotes liver cancer cell growth by the upregulation of FUSE-binding protein 1 expression.Int J Oncol. 2013 Mar;42(3):1093-104. doi: 10.3892/ijo.2013.1782. Epub 2013 Jan 18.
419 Downregulation and antiproliferative role of FHL3 in breast cancer.IUBMB Life. 2011 Sep;63(9):764-71. doi: 10.1002/iub.502.
420 Trans-acting non-synonymous variant of FOXA1 predisposes to hepatocellular carcinoma through modulating FOXA1-ER transcriptional program and may have undergone natural selection.Carcinogenesis. 2020 Apr 22;41(2):146-158. doi: 10.1093/carcin/bgz136.
421 Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors.Sci Rep. 2017 Apr 4;7(1):641. doi: 10.1038/s41598-017-00219-3.
422 miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9.Onco Targets Ther. 2019 Mar 22;12:2149-2157. doi: 10.2147/OTT.S197326. eCollection 2019.
423 FUN14 Domain-Containing 1-Mediated Mitophagy Suppresses Hepatocarcinogenesis by Inhibition of Inflammasome Activation in Mice.Hepatology. 2019 Feb;69(2):604-621. doi: 10.1002/hep.30191. Epub 2019 Jan 7.
424 Dysadherin can enhance tumorigenesis by conferring properties of stem-like cells to hepatocellular carcinoma cells.J Hepatol. 2011 Jan;54(1):122-31. doi: 10.1016/j.jhep.2010.06.026. Epub 2010 Aug 26.
425 Two variants of the human hepatocellular carcinoma-associated HCAP1 gene and their effect on the growth of the human liver cancer cell line Hep3B.Genes Chromosomes Cancer. 2004 Jan;39(1):48-58. doi: 10.1002/gcc.10293.
426 GGPPS1 predicts the biological character of hepatocellular carcinoma in patients with cirrhosis.BMC Cancer. 2014 Apr 9;14:248. doi: 10.1186/1471-2407-14-248.
427 Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis.Toxicol Sci. 2019 Aug 1;170(2):273-282. doi: 10.1093/toxsci/kfz110.
428 Golgi protein 73 and its diagnostic value in liver diseases.Cell Prolif. 2019 Mar;52(2):e12538. doi: 10.1111/cpr.12538. Epub 2018 Oct 19.
429 Changes in S-adenosylmethionine synthetase in human liver cancer: molecular characterization and significance.Hepatology. 1996 Nov;24(5):1090-7. doi: 10.1002/hep.510240519.
430 Demethylation of the HACE1 gene promoter inhibits the proliferation of human liver cancer cells.Oncol Lett. 2019 May;17(5):4361-4368. doi: 10.3892/ol.2019.10139. Epub 2019 Mar 12.
431 Regression of Fibrosis Stage With Treatment Reduces Long-Term Risk of Liver Cancer in Patients With Hemochromatosis Caused by Mutation in HFE.Clin Gastroenterol Hepatol. 2020 Jul;18(8):1851-1857. doi: 10.1016/j.cgh.2019.10.010. Epub 2019 Oct 14.
432 TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients.BMC Cancer. 2012 Mar 8;12:85. doi: 10.1186/1471-2407-12-85.
433 Tg737 acts as a key driver of invasion and migration in liver cancer stem cells and correlates with poor prognosis in patients with hepatocellular carcinoma.Exp Cell Res. 2017 Sep 15;358(2):217-226. doi: 10.1016/j.yexcr.2017.06.021. Epub 2017 Jun 27.
434 ILF2 Directly Binds and Stabilizes CREB to Stimulate Malignant Phenotypes of Liver Cancer Cells.Anal Cell Pathol (Amst). 2019 Feb 10;2019:1575031. doi: 10.1155/2019/1575031. eCollection 2019.
435 IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma.BMC Gastroenterol. 2010 Oct 26;10:125. doi: 10.1186/1471-230X-10-125.
436 Integrin alpha 7 correlates with poor clinical outcomes, and it regulates cell proliferation, apoptosis and stemness via PTK2-PI3K-Akt signaling pathway in hepatocellular carcinoma.Cell Signal. 2020 Feb;66:109465. doi: 10.1016/j.cellsig.2019.109465. Epub 2019 Nov 5.
437 Expression of junB is markedly stimulated by glycyrrhizin in a human hepatoma cell line.Oncol Rep. 2011 Mar;25(3):609-17. doi: 10.3892/or.2011.1137. Epub 2011 Jan 10.
438 TIP60-dependent acetylation of the SPZ1-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer.Oncogene. 2019 Jan;38(4):518-532. doi: 10.1038/s41388-018-0457-z. Epub 2018 Aug 28.
439 KCNK levels are prognostic and diagnostic markers for hepatocellular carcinoma.Aging (Albany NY). 2019 Oct 2;11(19):8169-8182. doi: 10.18632/aging.102311. Epub 2019 Oct 2.
440 KLF11 promotes gastric cancer invasion and migration by increasing Twist1 expression.Neoplasma. 2019 Jan 15;66(1):92-100. doi: 10.4149/neo_2018_180325N201. Epub 2018 Sep 4.
441 Screening and identification of the tumor-associated antigen CK10, a novel potential liver cancer marker.FEBS Open Bio. 2017 Mar 21;7(5):627-635. doi: 10.1002/2211-5463.12122. eCollection 2017 May.
442 Keratin 23 Is a Peroxisome Proliferator-Activated Receptor Alpha-Dependent, MYC-Amplified Oncogene That Promotes Hepatocyte Proliferation.Hepatology. 2019 Jul;70(1):154-167. doi: 10.1002/hep.30530. Epub 2019 Mar 20.
443 Oncoprotein LAMTOR5 Activates GLUT1 Via Upregulating NF-B in Liver Cancer.Open Med (Wars). 2019 Feb 26;14:264-270. doi: 10.1515/med-2019-0022. eCollection 2019.
444 Low density lipoprotein receptor class A domain containing 4 (LDLRAD4) promotes tumorigenesis of hepatic cancer cells.Exp Cell Res. 2017 Nov 15;360(2):189-198. doi: 10.1016/j.yexcr.2017.09.005. Epub 2017 Sep 6.
445 Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development.Liver Int. 2017 Jun;37(6):879-887. doi: 10.1111/liv.13341. Epub 2016 Dec 28.
446 Derepression of LOXL4 inhibits liver cancer growth by reactivating compromised p53.Cell Death Differ. 2019 Nov;26(11):2237-2252. doi: 10.1038/s41418-019-0293-x. Epub 2019 Feb 6.
447 Nuclear receptor CAR-regulated expression of the FAM84A gene during the development of mouse liver tumors.Int J Oncol. 2011 Jun;38(6):1511-20. doi: 10.3892/ijo.2011.980. Epub 2011 Mar 17.
448 Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.Am J Pathol. 2001 Sep;159(3):945-53. doi: 10.1016/S0002-9440(10)61770-1.
449 SPAG9/MKK3/p38 axis is a novel therapeutic target for liver cancer.Oncol Rep. 2019 Apr;41(4):2329-2336. doi: 10.3892/or.2019.6987. Epub 2019 Jan 30.
450 Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/-catenin Signaling Pathway.Molecules. 2019 Jan 22;24(3):393. doi: 10.3390/molecules24030393.
451 MARVELD1 attenuates arsenic trioxide-induced apoptosis in liver cancer cells by inhibiting reactive oxygen species production. Ann Transl Med. 2019 May;7(9):200. doi: 10.21037/atm.2019.04.38.
452 Absent expression of miR-30a promotes the growth of lung cancer cells by targeting MEF2D.Oncol Lett. 2018 Jul;16(1):1173-1179. doi: 10.3892/ol.2018.8719. Epub 2018 May 16.
453 RNA m(6)A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail.Nat Commun. 2019 May 6;10(1):2065. doi: 10.1038/s41467-019-09865-9.
454 LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib-mediated death via inhibiting the AMPK-Mfn2 signaling pathway.Cancer Cell Int. 2019 Mar 18;19:60. doi: 10.1186/s12935-019-0778-1. eCollection 2019.
455 Specific delivery of microRNA93 into HBV-replicating hepatocytes downregulates protein expression of liver cancer susceptible gene MICA.Oncotarget. 2014 Jul 30;5(14):5581-90. doi: 10.18632/oncotarget.2143.
456 Genetic ablation of TAZ induces HepG2 liver cancer cell apoptosis through activating the CaMKII/MIEF1 signaling pathway.Onco Targets Ther. 2019 Mar 1;12:1765-1779. doi: 10.2147/OTT.S196142. eCollection 2019.
457 Sirtuin-1/Mitochondrial Ribosomal Protein S5 Axis Enhances the Metabolic Flexibility of Liver Cancer Stem Cells.Hepatology. 2019 Oct;70(4):1197-1213. doi: 10.1002/hep.30622. Epub 2019 Jun 26.
458 Metallothionein 1 h tumour suppressor activity in prostate cancer is mediated by euchromatin methyltransferase 1.J Pathol. 2013 Jun;230(2):184-93. doi: 10.1002/path.4169.
459 Loss of NDRG2 in liver microenvironment inhibits cancer liver metastasis by regulating tumor associate macrophages polarization.Cell Death Dis. 2018 Feb 14;9(2):248. doi: 10.1038/s41419-018-0284-8.
460 Niemann-Pick type C2 protein regulates liver cancer progression via modulating ERK1/2 pathway: Clinicopathological correlations and therapeutical implications.Int J Cancer. 2015 Sep 15;137(6):1341-51. doi: 10.1002/ijc.29507. Epub 2015 Mar 24.
461 NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.Cell Death Dis. 2016 Jun 23;7(6):e2269. doi: 10.1038/cddis.2016.175.
462 Downregulation of nucleolar and spindle-associated protein 1 expression suppresses liver cancer cell function.Exp Ther Med. 2019 Apr;17(4):2969-2978. doi: 10.3892/etm.2019.7314. Epub 2019 Feb 26.
463 Inhibiting the Hexosamine Biosynthetic Pathway Lowers O-GlcNAcylation Levels and Sensitizes Cancer to Environmental Stress.Biochemistry. 2020 Sep 1;59(34):3169-3179. doi: 10.1021/acs.biochem.9b00560. Epub 2019 Nov 18.
464 Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.Onco Targets Ther. 2017 Mar 8;10:1475-1485. doi: 10.2147/OTT.S92389. eCollection 2017.
465 Cancers Due to Excess Weight, Low Physical Activity, and Unhealthy Diet.Dtsch Arztebl Int. 2018 Sep 3;115(35-36):578-585. doi: 10.3238/arztebl.2018.0578.
466 Lnc-PDZD7 contributes to stemness properties and chemosensitivity in hepatocellular carcinoma through EZH2-mediated ATOH8 transcriptional repression.J Exp Clin Cancer Res. 2019 Feb 20;38(1):92. doi: 10.1186/s13046-019-1106-2.
467 PES1 In Liver Cancer: A Prognostic Biomarker With Tumorigenic Roles.Cancer Manag Res. 2019 Nov 14;11:9641-9653. doi: 10.2147/CMAR.S226471. eCollection 2019.
468 Metformin attenuates hepatoma cell proliferation by decreasing glycolytic flux through the HIF-1/PFKFB3/PFK1 pathway.Life Sci. 2019 Dec 15;239:116966. doi: 10.1016/j.lfs.2019.116966. Epub 2019 Oct 15.
469 The POLR2E rs3787016 polymorphism is strongly associated with the risk of female breast and cervical cancer.Pathol Res Pract. 2019 May;215(5):1061-1065. doi: 10.1016/j.prp.2019.02.015. Epub 2019 Feb 27.
470 Cyclophilin J is a novel peptidyl-prolyl isomerase and target for repressing the growth of hepatocellular carcinoma.PLoS One. 2015 May 28;10(5):e0127668. doi: 10.1371/journal.pone.0127668. eCollection 2015.
471 Protein phosphatase 2 regulatory subunit B''Alpha silencing inhibits tumor cell proliferation in liver cancer.Cancer Med. 2019 Dec;8(18):7741-7753. doi: 10.1002/cam4.2620. Epub 2019 Oct 24.
472 Dependence of artesunate on long noncoding RNA-RP11 to inhibit epithelial-mesenchymal transition of hepatocellular carcinoma.J Cell Biochem. 2019 Apr;120(4):6026-6034. doi: 10.1002/jcb.27889. Epub 2018 Oct 18.
473 Expression of liver cancer associated gene HCCA3.World J Gastroenterol. 2001 Dec;7(6):821-5. doi: 10.3748/wjg.v7.i6.821.
474 Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1.Oncol Rep. 2017 Jan;37(1):273-280. doi: 10.3892/or.2016.5248. Epub 2016 Nov 15.
475 Changes in Radixin Expression and Interaction with Efflux Transporters in the Liver of Adjuvant-Induced Arthritic Rats.Inflammation. 2020 Feb;43(1):85-94. doi: 10.1007/s10753-019-01097-9.
476 RecQL1 DNA repair helicase: A potential tumor marker and therapeutic target against hepatocellular carcinoma.Int J Mol Med. 2010 Apr;25(4):537-45. doi: 10.3892/ijmm_00000375.
477 Over-expression of regulator of G protein signaling 5 promotes tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma cells.J Surg Oncol. 2013 Sep;108(3):192-6. doi: 10.1002/jso.23367. Epub 2013 Jul 19.
478 8-bromo-5-hydroxy-7-methoxychrysin targeting for inhibition of the properties of liver cancer stem cells by modulation of Twist signaling.Int J Oncol. 2013 Nov;43(5):1719-29. doi: 10.3892/ijo.2013.2071. Epub 2013 Aug 21.
479 Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity.Cell Death Dis. 2017 May 4;8(5):e2766. doi: 10.1038/cddis.2017.165.
480 Tudor domain-containing protein 4 as a potential cancer/testis antigen in liver cancer.Tohoku J Exp Med. 2011 May;224(1):41-6. doi: 10.1620/tjem.224.41.
481 Prognostic value of increased expression of RACO-1 in patients with hepatitis B-related hepatocellular carcinoma.Ther Clin Risk Manag. 2017 Feb 15;13:191-200. doi: 10.2147/TCRM.S125331. eCollection 2017.
482 Synthesis, Docking Studies into CDK-2 and Anticancer Activity of New Derivatives Based Pyrimidine Scaffold and Their Derived Glycosides.Mini Rev Med Chem. 2019;19(13):1093-1110. doi: 10.2174/1389557519666190312165717.
483 MicroRNA-300 inhibits the growth of hepatocellular carcinoma cells by downregulating CREPT/Wnt/-catenin signaling.Oncol Lett. 2019 Oct;18(4):3743-3753. doi: 10.3892/ol.2019.10712. Epub 2019 Aug 5.
484 Liver haploinsufficiency of RuvBL1 causes hepatic insulin resistance and enhances hepatocellular carcinoma progression.Int J Cancer. 2020 Jun 15;146(12):3410-3422. doi: 10.1002/ijc.32787. Epub 2019 Nov 28.
485 New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation.Gastroenterology. 2019 Dec;157(6):1615-1629.e17. doi: 10.1053/j.gastro.2019.08.022. Epub 2019 Aug 22.
486 Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma.J Hepatol. 2006 Dec;45(6):825-35. doi: 10.1016/j.jhep.2006.06.016. Epub 2006 Jul 28.
487 Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing.Oncogene. 2014 Sep 25;33(39):4786-94. doi: 10.1038/onc.2013.424. Epub 2013 Oct 21.
488 Elevation of SHARPIN Protein Levels in Prostate Adenocarcinomas Promotes Metastasis and Impairs Patient Survivals.Prostate. 2017 May;77(7):718-728. doi: 10.1002/pros.23302. Epub 2017 Feb 23.
489 SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.J Exp Clin Cancer Res. 2019 Jun 13;38(1):252. doi: 10.1186/s13046-019-1246-4.
490 A novel SOCS5/miR-18/miR-25 axis promotes tumorigenesis in liver cancer.Int J Cancer. 2019 Jan 15;144(2):311-321. doi: 10.1002/ijc.31857. Epub 2018 Nov 9.
491 SPIN1 triggers abnormal lipid metabolism and enhances tumor growth in liver cancer.Cancer Lett. 2020 Feb 1;470:54-63. doi: 10.1016/j.canlet.2019.11.032. Epub 2019 Nov 29.
492 Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways.J Hepatol. 2012 Sep;57(3):577-83. doi: 10.1016/j.jhep.2012.04.026. Epub 2012 May 19.
493 Expression of protein TARBP1 in human hepatocellular carcinoma and its prognostic significance.Int J Clin Exp Pathol. 2015 Aug 1;8(8):9089-96. eCollection 2015.
494 Apicidin-resistant HA22T hepatocellular carcinoma cells strongly activated the Wnt/-catenin signaling pathway and MMP-2 expression via the IGF-IR/PI3K/Akt signaling pathway enhancing cell metastatic effect.Biosci Biotechnol Biochem. 2013;77(12):2397-404. doi: 10.1271/bbb.130503. Epub 2013 Dec 7.
495 Co-delivery of LETM1 and CTMP synergistically inhibits tumor growth in H-ras12V liver cancer model mice.Cancer Gene Ther. 2013 Mar;20(3):186-94. doi: 10.1038/cgt.2013.6. Epub 2013 Feb 8.
496 Sp1-mediated ectopic expression of T-cell lymphoma invasion and metastasis 2 in hepatocellular carcinoma.Cancer Med. 2016 Mar;5(3):465-77. doi: 10.1002/cam4.611. Epub 2016 Jan 14.
497 TIGD1, a gene of unknown function, involves cell-cycle progression and correlates with poor prognosis in human cancer.J Cell Biochem. 2019 Jun;120(6):9758-9767. doi: 10.1002/jcb.28256. Epub 2018 Dec 11.
498 The positive correlation of TIPRL with LC3 and CD133 contributes to cancer aggressiveness: potential biomarkers for early liver cancer.Sci Rep. 2019 Nov 14;9(1):16802. doi: 10.1038/s41598-019-53191-5.
499 Decreased expression of ZO-1 is associated with tumor metastases in liver cancer.Oncol Lett. 2019 Feb;17(2):1859-1864. doi: 10.3892/ol.2018.9765. Epub 2018 Nov 27.
500 Adenovirus-mediated delivery of siRNA targeting TM4SF4 attenuated liver cancer cell growth in vitro and in vivo.Acta Biochim Biophys Sin (Shanghai). 2013 Mar;45(3):213-9. doi: 10.1093/abbs/gms115. Epub 2013 Jan 7.
501 Abnormal accumulation of human transmembrane (TMEM)-176A and 176B proteins is associated with cancer pathology.Acta Histochem. 2012 Nov;114(7):705-12. doi: 10.1016/j.acthis.2011.12.006. Epub 2012 Jan 12.
502 The Expression of TMEM74 in Liver Cancer and Lung Cancer Correlating With Survival Outcomes.Appl Immunohistochem Mol Morphol. 2019 Sep;27(8):618-625. doi: 10.1097/PAI.0000000000000659.
503 Effects of TMEM9 gene on cell progression in hepatocellular carcinoma by RNA interference.Oncol Rep. 2016 Jul;36(1):299-305. doi: 10.3892/or.2016.4821. Epub 2016 May 19.
504 Tropomodulin3 promotes liver cancer progression by activating the MAPK/ERK signaling pathway.Oncol Rep. 2019 May;41(5):3060-3068. doi: 10.3892/or.2019.7052. Epub 2019 Mar 7.
505 The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis.Nat Commun. 2019 Jan 8;10(1):83. doi: 10.1038/s41467-018-07922-3.
506 miR-149* Suppresses Liver Cancer Progression by Down-Regulating Tumor Necrosis Factor Receptor 1-Associated Death Domain Protein Expression.Am J Pathol. 2020 Feb;190(2):469-483. doi: 10.1016/j.ajpath.2019.10.010. Epub 2019 Nov 26.
507 Construction of Traf3 knockout liver cancer cell line using CRISPR/Cas9 system.J Cell Biochem. 2019 Sep;120(9):14908-14915. doi: 10.1002/jcb.28753. Epub 2019 Apr 23.
508 KIAA1114, a full-length protein encoded by the trophinin gene, is a novel surface marker for isolating tumor-initiating cells of multiple hepatocellular carcinoma subtypes.Oncotarget. 2014 Mar 15;5(5):1226-40. doi: 10.18632/oncotarget.1677.
509 High Trophinin-Associated Protein Expression Is an Independent Predictor of Poor Survival in Liver Cancer.Dig Dis Sci. 2019 Jan;64(1):137-143. doi: 10.1007/s10620-018-5315-x. Epub 2018 Oct 4.
510 Depletion of TRRAP Induces p53-Independent Senescence in Liver Cancer by Down-Regulating Mitotic Genes.Hepatology. 2020 Jan;71(1):275-290. doi: 10.1002/hep.30807. Epub 2019 Aug 11.
511 Epigenetic silencing of ALX4 regulates microcystin-LR induced hepatocellular carcinoma through the P53 pathway.Sci Total Environ. 2019 Sep 15;683:317-330. doi: 10.1016/j.scitotenv.2019.05.144. Epub 2019 May 15.
512 HBV upregulates AP-1 complex subunit mu-1 expression via the JNK pathway to promote proliferation of liver cancer cells.Oncol Lett. 2019 Jul;18(1):456-464. doi: 10.3892/ol.2019.10291. Epub 2019 Apr 30.
513 HBV triggers APOBEC2 expression through miR?22 regulation and affects the proliferation of liver cancer cells.Int J Oncol. 2019 Nov;55(5):1137-1148. doi: 10.3892/ijo.2019.4870. Epub 2019 Sep 4.
514 Arf6-driven endocytic recycling of CD147 determines HCC malignant phenotypes.J Exp Clin Cancer Res. 2019 Nov 21;38(1):471. doi: 10.1186/s13046-019-1464-9.
515 Familial intrahepatic cholestasis: New and wide perspectives.Dig Liver Dis. 2019 Jul;51(7):922-933. doi: 10.1016/j.dld.2019.04.013. Epub 2019 May 16.
516 LncRNA HAND2-AS1 promotes liver cancer stem cell self-renewal via BMP signaling.EMBO J. 2019 Sep 2;38(17):e101110. doi: 10.15252/embj.2018101110. Epub 2019 Jul 23.
517 CBX3/HP1 promotes tumor proliferation and predicts poor survival in hepatocellular carcinoma.Aging (Albany NY). 2019 Aug 2;11(15):5483-5497. doi: 10.18632/aging.102132. Epub 2019 Aug 2.
518 CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma.Mol Med Rep. 2016 Aug;14(2):1509-14. doi: 10.3892/mmr.2016.5410. Epub 2016 Jun 17.
519 Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms.J Exp Clin Cancer Res. 2019 Nov 8;38(1):458. doi: 10.1186/s13046-019-1444-0.
520 Role of miR-182-5p overexpression in trichloroethylene-induced abnormal cell cycle functions in human HepG2 cells.J Toxicol Environ Health A. 2019;82(16):920-927. doi: 10.1080/15287394.2019.1666550. Epub 2019 Sep 15.
521 Claudin-1 silencing increases sensitivity of liver cancer HepG2 cells to 5-fluorouracil by inhibiting autophagy.Oncol Lett. 2019 Dec;18(6):5709-5716. doi: 10.3892/ol.2019.10967. Epub 2019 Oct 8.
522 DIS3L2 Promotes Progression of Hepatocellular Carcinoma via hnRNP U-Mediated Alternative Splicing.Cancer Res. 2019 Oct 1;79(19):4923-4936. doi: 10.1158/0008-5472.CAN-19-0376. Epub 2019 Jul 22.
523 Upregulation of EPS8L3 is associated with tumorigenesis and poor prognosis in patients with liver cancer.Mol Med Rep. 2019 Sep;20(3):2493-2499. doi: 10.3892/mmr.2019.10471. Epub 2019 Jul 4.
524 Expression of Clusterin suppresses Cr(VI)-induced premature senescence through activation of PI3K/AKT pathway.Ecotoxicol Environ Saf. 2019 Nov 15;183:109465. doi: 10.1016/j.ecoenv.2019.109465. Epub 2019 Jul 31.
525 CRISPR/Cas9-based editing of a sensitive transcriptional regulatory element to achieve cell type-specific knockdown of the NEMO scaffold protein.PLoS One. 2019 Sep 25;14(9):e0222588. doi: 10.1371/journal.pone.0222588. eCollection 2019.
526 The Tumor Suppressor Interferon Regulatory Factor 2 Binding Protein 2 Regulates Hippo Pathway in Liver Cancer by a Feedback Loop in Mice.Hepatology. 2020 Jun;71(6):1988-2004. doi: 10.1002/hep.30961. Epub 2020 Feb 16.
527 Expression of La Ribonucleoprotein Domain Family Member 4B (LARP4B) in Liver Cancer and Their Clinical and Prognostic Significance.Dis Markers. 2019 Oct 22;2019:1569049. doi: 10.1155/2019/1569049. eCollection 2019.
528 Knockdown MTMR14 promotes cell apoptosis and inhibits migration in liver cancer cells.Gene. 2019 Apr 5;691:106-113. doi: 10.1016/j.gene.2018.11.099. Epub 2018 Dec 23.
529 COUP-TFII is a modulator of cell-type-specific genetic programs based on genomic localization maps.J Biotechnol. 2019 Aug 10;301:11-17. doi: 10.1016/j.jbiotec.2019.05.305. Epub 2019 May 31.
530 Nucleoporin Nup155 is part of the p53 network in liver cancer.Nat Commun. 2019 May 14;10(1):2147. doi: 10.1038/s41467-019-10133-z.
531 OGDHL Expression as a Prognostic Biomarker for Liver Cancer Patients.Dis Markers. 2019 Oct 17;2019:9037131. doi: 10.1155/2019/9037131. eCollection 2019.
532 The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein.Cancer Cell Int. 2019 Aug 27;19:222. doi: 10.1186/s12935-019-0936-5. eCollection 2019.
533 PGM5: a novel diagnostic and prognostic biomarker for liver cancer.PeerJ. 2019 Jun 11;7:e7070. doi: 10.7717/peerj.7070. eCollection 2019.
534 Phosphorylase Kinase Represents a Novel Prognostic Biomarker and Inhibits Malignant Phenotypes of Liver Cancer Cell.Int J Biol Sci. 2019 Sep 7;15(12):2596-2606. doi: 10.7150/ijbs.33278. eCollection 2019.
535 Identification and characterization of sexual dimorphismlinked gene expression profile in hepatocellular carcinoma.Oncol Rep. 2019 Sep;42(3):937-952. doi: 10.3892/or.2019.7217. Epub 2019 Jun 28.
536 Inhibition of PIKfyve using YM201636 suppresses the growth of liver cancer via the induction of autophagy.Oncol Rep. 2019 Mar;41(3):1971-1979. doi: 10.3892/or.2018.6928. Epub 2018 Dec 12.
537 Identification of downstream target genes regulated by CX43 in hepatocellular carcinoma.Neoplasma. 2019 Jun 29;66(6):870-878. doi: 10.4149/neo_2018_181225N995. Print 2019 Nov.
538 RETRACTED: HBV-encoded miR-2 functions as an oncogene by downregulating TRIM35 but upregulating RAN in liver cancer cells.EBioMedicine. 2019 Oct;48:117-129. doi: 10.1016/j.ebiom.2019.09.012. Epub 2019 Sep 14.
539 Plumbagin inhibits proliferation and induces apoptosis of hepatocellular carcinoma by downregulating the expression of SIVA.Drug Des Devel Ther. 2019 Apr 23;13:1289-1300. doi: 10.2147/DDDT.S200610. eCollection 2019.
540 SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer.EBioMedicine. 2019 Feb;40:406-421. doi: 10.1016/j.ebiom.2018.12.031. Epub 2018 Dec 26.
541 Silencing stomatin-like protein 2 attenuates tumor progression and inflammatory response through repressing CD14 in liver cancer.Onco Targets Ther. 2019 Sep 9;12:7361-7373. doi: 10.2147/OTT.S215131. eCollection 2019.
542 Tcf7l1 Acts as a Suppressor for the Self-Renewal of Liver Cancer Stem Cells and Is Regulated by IGF/MEK/ERK Signaling Independent of -Catenin.Stem Cells. 2019 Nov;37(11):1389-1400. doi: 10.1002/stem.3063. Epub 2019 Aug 26.
543 CCT3 acts upstream of YAP and TFCP2 as a potential target and tumour biomarker in liver cancer.Cell Death Dis. 2019 Sep 9;10(9):644. doi: 10.1038/s41419-019-1894-5.
544 TRIM29 prevents hepatocellular carcinoma progression by inhibiting Wnt/-catenin signaling pathway.Acta Biochim Biophys Sin (Shanghai). 2019 Jan 1;51(1):68-77. doi: 10.1093/abbs/gmy151.